changes in spinal cord morphology after T4 transection and olfactory ensheathing cell transplantation Tomas Kalincik a , , Katarina Jozefcikova a , Ratneswary Sutharsan b , Alan Mackay-Sim b , Pascal Carrive a , Phil M.E. Waite a a School of Medical Sciences , University of New South Wales , Sydney , NSW 2052 , Australia b National Centre for Adult Stem Cell Research , Eskitis Institute for Cell and Molecular Therapies , Griffith University , Nathan , QLD 4111 ,	10
changes	10
spinal cord morphology after T4 transection and olfactory ensheathing cell transplantation Tomas Kalincik a ,	21
spinal cord morphology	21
T4 transection and olfactory ensheathing cell transplantation Tomas Kalincik a ,	50
T4 transection	50
olfactory ensheathing cell transplantation Tomas Kalincik a	69
olfactory ensheathing cell transplantation Tomas	69
Kalincik a	120
Katarina Jozefcikova a	134
Katarina Jozefcikova	134
a	155
Ratneswary Sutharsan b	158
Alan Mackay-Sim b	182
Pascal Carrive a	201
Pascal Carrive	201
a	216
Phil M.E. Waite a a School of Medical Sciences , University of New South Wales	219
Phil M.E. Waite	219
a a School of Medical Sciences , University of New South Wales	235
a School	237
Medical Sciences	249
University of New South Wales	267
University	267
New South Wales	281
Sydney	298
NSW 2052	306
Australia b National Centre for Adult Stem Cell Research	316
Australia b National Centre	316
Adult Stem Cell Research	348
Eskitis Institute for Cell and Molecular Therapies	374
Eskitis Institute	374
Cell and Molecular Therapies	396
Griffith University	426
Nathan	447
QLD 4111	455
Australia	465
a b	477
t r a c t Spinal cord transection at T4 results in severe damage of the nervous tissue , with impairment of motor , sensory and autonomic functions	483
t r	483
a c t Spinal cord transection at T4	487
a c t Spinal cord transection	487
T4	520
severe damage of the nervous tissue	534
severe damage	534
the nervous tissue	551
impairment of motor , sensory and autonomic functions	576
impairment	576
motor , sensory and autonomic functions	590
Transplantation of olfactory ensheathing cells -LRB- OECs -RRB-	630
Transplantation of olfactory ensheathing cells	630
Transplantation	630
olfactory ensheathing cells	649
OECs	678
the potential to improve these functions through a number of mechanisms , which include facilitation of regeneration and neuroprotection	688
these functions	713
a number of mechanisms , which include facilitation of regeneration and neuroprotection	737
a number	737
mechanisms , which include facilitation of regeneration and neuroprotection	749
mechanisms	749
facilitation of regeneration and neuroprotection	775
facilitation	775
regeneration and neuroprotection	791
cardiovascular functions	829
we	855
OECs	885
the duration of autonomic dysreflexia	897
the duration	897
autonomic dysreflexia	913
evidence of regeneration	944
evidence	944
regeneration	956
the mechanisms underpinning this improvement	992
the mechanisms	992
this improvement	1020
we	1038
changes in selected morphological features -LRB- cavitation , non-cavity tissue loss , morphology of sympathetic preganglionic neurons and primary afferent fibre density -RRB- in the T4-transected rat spinal cord over 9 weeks , both in control and OEC-transplanted animals	1054
changes	1054
selected morphological features -LRB- cavitation , non-cavity tissue loss , morphology of sympathetic preganglionic neurons and primary afferent fibre density -RRB- in the T4-transected rat spinal cord over 9 weeks	1065
selected morphological features -LRB- cavitation , non-cavity tissue loss , morphology of sympathetic preganglionic neurons and primary afferent fibre density -RRB-	1065
selected morphological features	1065
cavitation , non-cavity tissue loss , morphology of sympathetic preganglionic neurons and primary afferent fibre density	1098
cavitation , non-cavity tissue loss	1098
cavitation	1098
non-cavity tissue loss	1110
morphology of sympathetic preganglionic neurons	1134
morphology	1134
sympathetic preganglionic neurons	1148
primary afferent fibre density	1186
the T4-transected rat spinal cord over 9 weeks	1221
the T4-transected rat spinal cord	1221
9 weeks	1260
control and OEC-transplanted animals	1277
T4 transection	1315
a number of structural changes : gradual formation of cavities , non-cavity tissue loss , a long-term increase in soma size of sympathetic preganglionic neurons and a temporary increase in the extent of their dendritic arbours	1337
a number of structural changes : gradual formation of cavities , non-cavity tissue loss	1337
a number of structural changes	1337
a number	1337
structural changes	1349
gradual formation of cavities , non-cavity tissue loss	1369
gradual formation	1369
cavities , non-cavity tissue loss	1390
cavities	1390
non-cavity tissue loss	1400
a long-term increase in soma size of sympathetic preganglionic neurons	1424
a long-term increase	1424
soma size of sympathetic preganglionic neurons	1448
soma size	1448
sympathetic preganglionic neurons	1461
a temporary increase in the extent of their dendritic arbours	1499
a temporary increase	1499
the extent of their dendritic arbours	1523
the extent	1523
their dendritic arbours	1537
an increase in the density of primary afferent fibres	1566
an increase	1566
the density of primary afferent fibres	1581
the density	1581
primary afferent fibres	1596
the lesion	1630
OECs	1642
the cavitation and normalised soma size of the sympathetic preganglionic neurons	1657
the cavitation and normalised soma size	1657
the sympathetic preganglionic neurons	1700
the lesion	1744
the extent of dendritic arbours	1773
the extent	1773
dendritic arbours	1787
the preganglionic neurons above the lesion	1808
the preganglionic neurons	1808
the lesion	1840
the OECs	1857
the normalisation of the dysreflexic hypertension	1884
the normalisation	1884
the dysreflexic hypertension	1905
tissue preservation	1942
normalisation of the morphology of the preganglionic neurons	1966
normalisation	1966
the morphology of the preganglionic neurons	1983
the morphology	1983
the preganglionic neurons	2001
the lesion	2037
the input	2065
the rostral preganglionic neurons , whose vasomotor control remains intact	2078
the rostral preganglionic neurons	2078
vasomotor control	2119
We	2153
these changes	2173
secretion of soluble trophic factors	2208
secretion	2208
soluble trophic factors	2221
the transplanted OECs	2248
Introduction Spinal cord injury -LRB- SCI -RRB-	2275
Introduction Spinal cord injury	2275
Introduction	2275
Spinal cord injury	2288
SCI	2308
both immediate and delayed neural tissue loss	2322
impairment of sensory , motor and autonomic functions	2382
impairment	2382
sensory , motor and autonomic functions	2396
tissue loss	2453
the formation of cavities within the spinal cord as well as an overall shrinkage of the nervous tissue adjacent to the injury site -LRB- Kakulas , 1999 ; Potas et al. , 2006 -RRB-	2480
the formation	2480
cavities within the spinal cord as well as an overall shrinkage of the nervous tissue adjacent to the injury site -LRB- Kakulas , 1999 ; Potas et al. , 2006 -RRB-	2497
cavities within the spinal cord	2497
cavities	2497
the spinal cord	2513
an overall shrinkage of the nervous tissue adjacent to the injury site -LRB- Kakulas , 1999 ; Potas et al. , 2006 -RRB-	2540
an overall shrinkage	2540
the nervous tissue adjacent to the injury site -LRB- Kakulas , 1999 ; Potas et al. , 2006 -RRB-	2564
the nervous tissue adjacent to the injury site	2564
the nervous tissue	2564
the injury site	2595
Kakulas , 1999 ; Potas et al. , 2006	2612
Kakulas	2612
1999 ; Potas et al.	2621
1999	2621
Potas et al.	2627
Potas	2627
et al.	2633
2006	2641
tissue loss	2656
the development of secondary injury	2669
the development	2669
secondary injury	2688
plastic changes	2724
neuronal systems not directly disrupted by the traumatic event	2743
neuronal systems	2743
the traumatic event	2786
example	2811
primary afferent fibres	2833
the dorsal horn and plasticity of propriospinal connections	2864
the dorsal horn and plasticity	2864
propriospinal connections	2898
4 weeks of the SCI	2937
4 weeks	2937
the SCI	2948
the spinal segments	2959
the injury -LRB- Cameron et al. , 2006 ; Hou et al. , 2008 ; Hou et al. , 2009 ; Krenz et al. , 1999 -RRB-	2989
the injury	2989
Cameron et al. , 2006 ; Hou et al. , 2008 ; Hou et al. , 2009 ; Krenz et al. , 1999	3001
Cameron	3001
et al. , 2006 ; Hou et al. , 2008 ; Hou et al. , 2009 ; Krenz et al. , 1999	3009
et al. , 2006	3009
et al.	3009
2006	3017
Hou et al. , 2008	3023
Hou	3023
et al. , 2008	3027
et al.	3027
2008	3035
Hou et al. , 2009	3041
Hou	3041
et al. , 2009	3045
et al.	3045
2009	3053
Krenz et al. , 1999	3059
Krenz	3059
et al. , 1999	3065
et al.	3065
1999	3073
changes in the morphology of the sympathetic preganglionic neurons -LRB- SPNs -RRB-	3093
changes	3093
the morphology of the sympathetic preganglionic neurons -LRB- SPNs -RRB-	3104
the morphology	3104
the sympathetic preganglionic neurons -LRB- SPNs -RRB-	3122
the sympathetic preganglionic neurons	3122
SPNs	3161
the early post-injury period -LRB- Krassioukov andWeaver , 1996 ; Krenz andWeaver , 1998a -RRB-	3184
the early post-injury period	3184
Krassioukov andWeaver , 1996 ; Krenz andWeaver , 1998a	3214
Krassioukov andWeaver	3214
1996 ; Krenz andWeaver	3237
1996	3237
Krenz andWeaver	3243
1998a	3260
All these changes	3268
an important role	3305
the pathophysiology of autonomic dysreflexia , an episodic disturbance of autonomic functions , which may lead to serious consequences and death	3326
the pathophysiology	3326
autonomic dysreflexia , an episodic disturbance of autonomic functions , which may lead to serious consequences and death	3349
autonomic dysreflexia	3349
an episodic disturbance of autonomic functions , which may lead to serious consequences and death	3372
an episodic disturbance	3372
autonomic functions , which may lead to serious consequences and death	3399
autonomic functions	3399
serious consequences and death	3438
It	3470
olfactory ensheathing cells -LRB- OECs -RRB-	3487
olfactory ensheathing cells	3487
OECs	3516
the potential to assist regeneration in the injured spinal cord and thus contribute to improved functional outcome following SCI -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	3527
regeneration	3551
the injured spinal cord	3567
improved functional outcome following SCI -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	3614
improved functional outcome	3614
SCI -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	3652
SCI	3652
Li	3657
et al. , 1998 ; Ramon-Cueto et al. , 2000	3660
et al.	3660
1998 ; Ramon-Cueto et al.	3668
1998	3668
Ramon-Cueto et al.	3674
Ramon-Cueto	3674
et al.	3686
2000	3694
We	3701
transplantation of OECs	3720
transplantation	3720
OECs	3739
autonomic dysreflexia	3756
rats with T4 spinal cord transection , possibly through alteration of the morphology of the SPNs adjacent to the injury -LRB- Kalincik et al. , 2010 -RRB-	3781
rats with T4 spinal cord transection	3781
rats	3781
T4 spinal cord transection	3791
alteration of the morphology of the SPNs adjacent to the injury -LRB- Kalincik et al. , 2010 -RRB-	3836
alteration	3836
the morphology of the SPNs adjacent to the injury -LRB- Kalincik et al. , 2010 -RRB-	3850
the morphology	3850
the SPNs adjacent to the injury -LRB- Kalincik et al. , 2010 -RRB-	3868
the SPNs	3868
the injury -LRB- Kalincik et al. , 2010 -RRB-	3889
the injury	3889
Kalincik	3901
et al. , 2010	3910
et al.	3910
2010	3918
the effects of OECs on tissue injury , such as cavitation and shrinkage , and on sprouting of primary afferent fibres	3934
the effects	3934
OECs on tissue injury , such as cavitation and shrinkage , and on sprouting of primary afferent fibres	3949
OECs on tissue injury	3949
OECs	3949
tissue injury	3957
cavitation and shrinkage	3980
primary afferent fibres	4026
high thoracic transection	4082
this study	4112
we	4123
formation of cavities and non-cavity tissue loss	4136
formation	4136
cavities and non-cavity tissue loss	4149
cavities	4149
non-cavity tissue loss	4162
primary afferent fibres within the dorsal horn and morphometric parameters of SPNs in the spinal segments adjacent to a spinal cord transection	4199
primary afferent fibres within the dorsal horn	4199
primary afferent fibres	4199
the dorsal horn	4230
morphometric parameters of SPNs in the spinal segments adjacent to a spinal cord transection	4250
morphometric parameters	4250
SPNs in the spinal segments adjacent to a spinal cord transection	4277
SPNs	4277
the spinal segments adjacent to a spinal cord transection	4285
the spinal segments	4285
a spinal cord transection	4317
the level of T4	4346
the level	4346
T4	4359
we	4376
the effects of OEC transplantation	4388
the effects	4388
OEC transplantation	4403
these morphological features	4426
Materials and methods 2.1 .	4460
Materials and methods 2.1	4460
Materials	4460
methods 2.1	4474
Animals All experimental protocols and procedures	4487
Animals	4487
All experimental protocols and procedures	4495
the Animal Care and Ethics Committee of the University of New South Wales in accordance	4554
the Animal Care and Ethics Committee	4554
the University of New South Wales in accordance	4594
the University	4594
New South Wales in accordance	4612
New South Wales	4612
accordance	4631
the guidelines of the National Health and Medical Research Council of Australia	4647
the guidelines of the National Health	4647
the guidelines	4647
the National Health	4665
Medical Research Council of Australia	4689
Medical Research Council	4689
Australia	4717
Experiments	4728
30 naive male Australian Albino Wistar rats -LRB- Biological Resources Centre , University of New South Wales , Sydney , Australia -RRB- aged 11 - 14 weeks	4758
30 naive male Australian Albino Wistar rats -LRB- Biological Resources Centre , University of New South Wales , Sydney , Australia -RRB- aged 11	4758
30 naive male Australian Albino Wistar rats -LRB- Biological Resources Centre , University of New South Wales , Sydney , Australia -RRB-	4758
30 naive male Australian Albino Wistar rats	4758
Biological Resources Centre , University of New South Wales , Sydney , Australia	4803
Biological Resources Centre	4803
University of New South Wales	4832
University	4832
New South Wales	4846
Sydney , Australia	4863
11	4887
14 weeks	4891
350 -- 400 g	4913
350	4913
400 g	4917
The animals	4924
plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	4962
plastic home boxes	4962
65 × 40 × 22 cm	4982
65 × 40 ×	4982
65 ×	4982
40 ×	4985
22 cm	4988
ad-lib food and water	5015
a 12-h light/dark cycle	5055
2.2	5080
Cell preparation Cultures of green fluorescent protein -LRB- GFP -RRB- - expressing OECs	5085
Cell preparation Cultures	5085
green fluorescent protein -LRB- GFP -RRB- - expressing OECs	5114
green fluorescent protein	5114
GFP	5141
OECs	5157
Kalincik et al. , 2010	5190
Kalincik	5190
et al.	5199
2010	5207
olfactory lamina propria harvested from Australian Albino Wistar male rats -LRB- 8 weeks of age -RRB-	5223
olfactory lamina propria	5223
Australian Albino Wistar male rats	5263
8 weeks of age	5299
8 weeks	5299
age	5310
0.25 % collagenase type IA	5334
0.25 %	5334
collagenase type IA	5340
neurotrophin 3 -LRB- 50 ng/ml -RRB- , which is known to enhance survival of OECs in culture and increase their purity to close to 100 % -LRB- Bianco et al. , 2004 -RRB-	5378
neurotrophin 3 -LRB- 50 ng/ml -RRB-	5378
neurotrophin 3	5378
50 ng/ml	5394
survival of OECs in culture	5431
survival	5431
OECs in culture	5443
OECs	5443
culture	5451
their purity to close to 100 % -LRB- Bianco et al. , 2004 -RRB-	5472
100 % -LRB- Bianco et al. , 2004 -RRB-	5497
100 %	5497
Bianco	5503
et al. , 2004	5510
et al.	5510
2004	5518
90 % of cells	5530
90 %	5530
cells	5537
p75NFR	5567
1:200 , monoclonal ; Neubody , Thebarton , SA , Australia	5575
1:200	5575
monoclonal ; Neubody , Thebarton , SA , Australia	5582
monoclonal	5582
Neubody , Thebarton , SA , Australia	5594
fibrillary acidic protein -LRB- 1:250 , polyclonal GFAP ; Dako North America Inc. , CA , USA -RRB- , while no cells reacted with HNK1 antibody -LRB- 1:200 ; Sigma Castle Hill , NSW , Australia -RRB-	5639
fibrillary acidic protein	5639
1:250 , polyclonal GFAP ; Dako North America Inc. , CA , USA	5666
1:250	5666
polyclonal GFAP ; Dako North America Inc.	5673
polyclonal GFAP	5673
Dako North America Inc.	5690
CA , USA	5715
no cells	5731
HNK1 antibody -LRB- 1:200 ; Sigma Castle Hill , NSW , Australia -RRB-	5753
HNK1 antibody	5753
1:200 ; Sigma Castle Hill	5768
1:200	5768
Sigma Castle Hill	5775
NSW , Australia	5794
NSW	5794
Australia	5799
OECs	5811
humanised Renilla	5846
GFP using pFB-hrGFP retroviral supernatant -LRB- Stratagene , La Jolla , CA , USA -RRB-	5875
GFP	5875
pFB-hrGFP retroviral supernatant -LRB- Stratagene , La Jolla , CA , USA -RRB-	5885
pFB-hrGFP retroviral supernatant	5885
Stratagene	5919
La Jolla	5931
CA , USA	5941
a fluorescence-activated cell sorter -LRB- BD FACS Aria , BD Biosciences -RRB-	5966
a fluorescence-activated cell sorter	5966
BD FACS Aria , BD Biosciences	6004
BD FACS Aria	6004
BD Biosciences	6018
The viability and labelling of the modified OECs	6035
The viability and labelling	6035
the modified OECs	6066
the purpose of the present experiment	6102
the purpose	6102
the present experiment	6117
they	6144
GFP at least nine weeks	6182
GFP	6182
nine weeks	6195
injection	6212
rat spinal cord in other experiments in our laboratory -LRB- Dr. Frank Cloutier , unpublished results -RRB-	6227
rat spinal cord	6227
other experiments in our laboratory -LRB- Dr. Frank Cloutier , unpublished results -RRB-	6246
other experiments	6246
our laboratory -LRB- Dr. Frank Cloutier , unpublished results -RRB-	6267
our laboratory	6267
Dr. Frank Cloutier , unpublished results	6283
Dr. Frank Cloutier	6283
unpublished results	6303
2.3	6325
T4 spinal cord transection and OECs transplantation Transection at the level of spinal segment T4 was carried out as previously described -LRB- Kalincik et al. , 2010 -RRB- .	6330
T4 spinal cord transection and OECs transplantation Transection at the level of spinal segment T4 was carried out as previously	6330
T4	6330
spinal cord transection and OECs transplantation Transection at the level of spinal segment T4	6333
spinal cord transection and OECs transplantation Transection	6333
the level of spinal segment T4	6397
the level	6397
spinal segment T4	6410
Kalincik et al. , 2010	6469
Kalincik	6469
et al.	6478
2010	6486
24 rats	6502
a mixture of ketamine hydrochloride -LRB- 100 mg / kg i.p. ; Ketamine , Parnell Laboratories Pty. Ltd. , NSW , Australia -RRB- and xylazine -LRB- 7 mg/kg i.p. ; IliumXylazil-20 , Troy Laboratories Pty. Ltd. , NSW , Australia -RRB-	6534
a mixture	6534
ketamine hydrochloride -LRB- 100 mg / kg i.p. ; Ketamine , Parnell Laboratories Pty. Ltd. , NSW , Australia -RRB- and xylazine -LRB- 7 mg/kg i.p. ; IliumXylazil-20 , Troy Laboratories Pty. Ltd. , NSW , Australia -RRB-	6547
ketamine hydrochloride	6547
100 mg	6571
100	6571
mg	6575
kg i.p. ; Ketamine , Parnell Laboratories Pty. Ltd. , NSW , Australia	6579
kg i.p.	6579
kg	6579
Ketamine , Parnell Laboratories Pty. Ltd. , NSW , Australia	6588
Ketamine	6588
Parnell Laboratories Pty. Ltd.	6598
NSW	6630
Australia	6635
xylazine	6650
7 mg/kg i.p. ; IliumXylazil-20 , Troy Laboratories Pty. Ltd. , NSW , Australia	6660
7 mg/kg i.p. ; IliumXylazil-20 , Troy Laboratories Pty. Ltd. ,	6660
7 mg/kg i.p.	6660
7 mg/kg	6660
IliumXylazil-20 , Troy Laboratories Pty. Ltd. ,	6674
IliumXylazil-20	6674
Troy Laboratories Pty. Ltd.	6691
NSW , Australia	6720
the surgical site	6740
0.5 % bupivacaine hydrochloride -LRB- 0.1 ml ; bupivacaine , Pharmacia Pty. Ltd. , WA , Australia -RRB-	6794
0.5 % bupivacaine hydrochloride	6794
0.1 ml ; bupivacaine	6826
0.1 ml	6826
bupivacaine	6834
Pharmacia Pty. Ltd. , WA , Australia	6847
Pharmacia Pty. Ltd.	6847
WA , Australia	6868
Laminectomy of the T3 vertebra	6884
Laminectomy	6884
the T3 vertebra	6899
the spinal cord	6935
microscissors at the level of T4	6982
microscissors	6982
the level of T4	6999
the level	6999
T4	7012
the OEC-treated animals -LRB- n = 12 -RRB-	7019
the OEC-treated animals	7019
n	7044
12	7046
the emergent gap between the spinal cord stumps -LRB- approx. 1 mm -RRB-	7051
the emergent gap	7051
the spinal cord stumps -LRB- approx. 1 mm -RRB-	7076
the spinal cord stumps	7076
1 mm	7108
sterile porcine gelatine sponge -LRB- approx. 2 × 1 × 1 mm ; Gelfoam , Pharmacia & Upjohn Co.	7130
sterile porcine gelatine sponge -LRB- approx. 2 × 1 × 1 mm ;	7130
sterile porcine gelatine sponge	7130
2 × 1 × 1 mm	7171
2 × 1 ×	7171
2 ×	7171
1 ×	7173
1 mm	7175
Gelfoam , Pharmacia & Upjohn Co.	7181
Kalamazoo , Mi , USA -RRB- soaked in 2 μl of medium containing OECs -LRB- 500,000 cells/μl -RRB- , while in the control animals -LRB- n = 12 -RRB- Gelfoam soaked in 2 μl of culture medium	7213
Kalamazoo , Mi , USA -RRB-	7213
Kalamazoo	7213
Mi	7224
USA	7228
2 μl of medium	7243
2 μl	7243
medium	7251
OECs -LRB- 500,000 cells/μl -RRB-	7269
OECs	7269
500,000 cells/μl	7275
the control animals -LRB- n = 12 -RRB-	7303
the control animals	7303
n	7324
12	7326
Gelfoam	7330
2 μl of culture medium	7348
2 μl	7348
culture medium	7356
Another Gelfoam block	7386
the dorsal surface of the spinal cord	7422
the dorsal surface	7422
the spinal cord	7444
the nervous tissue	7473
connective tissue	7509
the wound	7531
2.4	7553
Post-operative care Following surgery , the animals	7558
Post-operative care	7558
surgery , the animals	7588
surgery	7588
the animals	7597
27 °C	7622
Normotonic sodium chloride -LRB- 0.9 % , 5 -- 10 ml -RRB- and cephalotin -LRB- 60 mg/kg , s.c. ; cephalotin sodium , VIC , Australia -RRB-	7629
Normotonic sodium chloride -LRB- 0.9 % , 5 -- 10 ml -RRB-	7629
Normotonic sodium chloride	7629
0.9 % , 5 -- 10 ml	7657
0.9 %	7657
5 -- 10 ml	7663
5	7663
10 ml	7665
cephalotin -LRB- 60 mg/kg , s.c. ; cephalotin sodium , VIC , Australia -RRB-	7676
cephalotin	7676
60 mg/kg , s.c. ; cephalotin sodium , VIC , Australia	7688
60 mg/kg	7688
s.c. ; cephalotin sodium	7698
s.c.	7698
cephalotin sodium	7704
VIC , Australia	7723
5 days	7788
Subcutaneous injections of the analgesic rimadyl -LRB- 5 mg/kg s.c. ; Carprofen , Australia Pty. Ltd. , Australia -RRB-	7796
Subcutaneous injections	7796
the analgesic rimadyl -LRB- 5 mg/kg s.c. ; Carprofen , Australia Pty. Ltd. , Australia -RRB-	7823
the analgesic rimadyl	7823
5 mg/kg s.c.	7846
Carprofen , Australia Pty. Ltd. , Australia	7860
Carprofen	7860
Australia Pty. Ltd.	7871
Australia	7892
3 days	7930
The urinary bladderwas	7938
2	7980
3 times daily	7982
3 times	7982
autonomous bladder voidance reflexes gradually reestablished	8002
autonomous bladder voidance reflexes	8002
2 weeks	8075
Inspection for skin irritation , ulcers , and haematuria	8085
Inspection	8085
skin irritation , ulcers , and haematuria	8100
skin irritation	8100
ulcers	8117
haematuria	8129
soiled animals	8163
minor wounds	8194
2.5	8216
Tissue fixation and sectioning	8221
1 week -LRB- n = 12 -RRB- and 4 weeks -LRB- n = 12 -RRB- post-injury	8255
1 week -LRB- n = 12 -RRB-	8255
1 week	8255
n	8263
12	8265
4 weeks -LRB- n = 12 -RRB- post-injury	8273
4 weeks -LRB- n = 12 -RRB-	8273
n	8282
12	8284
post-injury	8288
the animals in both the OEC-treated and the control groups	8301
the animals	8301
both the OEC-treated and the control groups	8316
the OEC-treated	8321
the control groups	8341
pentobarbitone	8384
normotonic sodium chloride -LRB- 30 s -RRB- and 4 % paraformaldehyde -LRB- 20 min ; Merck Schuchardt OHG , Hohenbrunn , Germany -RRB-	8432
normotonic sodium chloride -LRB- 30 s -RRB-	8432
normotonic sodium chloride	8432
30 s	8460
4 % paraformaldehyde -LRB- 20 min ; Merck Schuchardt OHG , Hohenbrunn , Germany -RRB-	8470
4 % paraformaldehyde	8470
20 min ; Merck Schuchardt OHG	8491
20 min	8491
Merck Schuchardt OHG	8499
Hohenbrunn , Germany	8521
Hohenbrunn	8521
Germany	8533
addition	8546
6 intact rats	8556
the same procedure	8590
Spinal cord segments T1 -- T7 were collected , postfixed in 4 % paraformaldehyde -LRB- 2 h -RRB- and cryoprotected in 30 % sucrose -LRB- 24 h -RRB- .	8610
Spinal cord segments T1	8610
T7	8634
4 % paraformaldehyde -LRB- 2 h -RRB-	8666
4 % paraformaldehyde	8666
2 h	8687
30 % sucrose -LRB- 24 h -RRB-	8713
30 % sucrose	8713
24 h	8726
The segments T2 -- T6 were cut on a cryostat into 35 μm thick horizontal sections .	8733
The segments T2	8733
T6	8749
a cryostat	8764
35 μm thick horizontal sections	8780
35 μm	8780
The sections	8813
gelatinised slides	8844
− 22 °C	8888
each animal	8900
three series	8913
NADPH-diaphorase	8943
two series	8961
hematoxylin-eosin	8990
one series	9009
GFP	9036
one series	9044
the examination of unlabelled GFP	9078
the examination	9078
unlabelled GFP	9097
Segments T1 and T7	9113
Segments T1	9113
T7	9129
a cryostat	9144
35 μm thick transverse sections	9160
35 μm	9160
calcitonin-gene related peptide -LRB- CGRP -RRB-	9208
calcitonin-gene related peptide	9208
CGRP	9241
2.6	9248
Histochemistry for NADPH-diaphorase NADPH-diaphorase staining of sympathetic preganglionic neurons	9253
Histochemistry	9253
NADPH-diaphorase NADPH-diaphorase staining of sympathetic preganglionic neurons	9272
NADPH-diaphorase NADPH-diaphorase staining	9272
sympathetic preganglionic neurons	9318
a standard protocol -LRB- Carrive and Paxinos , 1994	9381
a standard protocol -LRB- Carrive and Paxinos	9381
a standard protocol	9381
Paxinos	9414
1994	9423
horizontal spinal cord sections	9439
phosphate buffered saline for 1 h and incubated in 0.05 % solution of NADPH -LRB- reduced NADPH , Sigma-Aldrich Pty. Ltd. , NSW , Australia -RRB- , 0.0125 % nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB- and 0.5 % triton-X in phosphate buffer -LRB- pH = 7.4 -RRB-	9486
phosphate	9486
saline for 1 h	9505
saline	9505
1 h	9516
0.05 % solution of NADPH -LRB- reduced NADPH , Sigma-Aldrich Pty. Ltd. , NSW , Australia -RRB-	9537
0.05 % solution	9537
NADPH	9555
NADPH , Sigma-Aldrich Pty. Ltd. , NSW , Australia	9570
NADPH	9570
Sigma-Aldrich Pty. Ltd.	9577
NSW	9602
Australia	9607
0.0125 % nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB- and 0.5 % triton-X in phosphate buffer -LRB- pH = 7.4 -RRB-	9619
0.0125 % nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB-	9619
0.0125 %	9619
nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB-	9627
nitroblue tetrazolium	9627
Sigma Chemical Co.	9650
MO	9670
USA	9674
0.5 % triton-X in phosphate buffer -LRB- pH = 7.4 -RRB-	9683
0.5 % triton-X	9683
phosphate buffer -LRB- pH = 7.4 -RRB-	9700
phosphate buffer	9700
pH	9718
7.4	9721
The tissue	9727
2 h at 37 °C	9762
2 h	9762
37 °C	9769
room temperature for 4 h	9792
room temperature	9792
4 h	9813
The reaction	9818
rinses in phosphate buffer and distilled water	9849
rinses	9849
phosphate buffer and distilled water	9859
phosphate buffer	9859
distilled water	9880
The sections	9897
overnight , cleared in 100 % ethanol for 4 -- 6 h ,	9925
overnight	9925
100 % ethanol for 4 -- 6 h	9947
100 % ethanol for 4	9947
100 % ethanol	9947
4	9964
6 h	9966
DAKO	9984
a light microscope -LRB- Olympus BX51 + DP70 -RRB-	10009
a light microscope	10009
Olympus BX51 + DP70	10029
Olympus BX51	10029
DP70	10042
2.7	10049
Immunohistochemistry CGRP , a cyclic neuropeptide present in the primary afferent sensory neurons ,	10054
Immunohistochemistry CGRP	10054
a cyclic neuropeptide present in the primary afferent sensory neurons	10081
a cyclic neuropeptide	10081
the primary afferent sensory neurons	10114
a polyclonal rabbit anti-rat CGRP primary antibody -LRB- 1:10,000 ; C8198 , Sigma-Aldrich , MI , USA -RRB- , which was prepared against synthetic rat CGRP	10170
a polyclonal rabbit anti-rat CGRP primary antibody -LRB- 1:10,000 ; C8198 , Sigma-Aldrich , MI , USA -RRB-	10170
a polyclonal rabbit	10170
anti-rat CGRP primary antibody -LRB- 1:10,000 ; C8198 , Sigma-Aldrich , MI , USA -RRB-	10190
anti-rat CGRP primary antibody	10190
1:10,000	10222
C8198 , Sigma-Aldrich , MI , USA	10232
C8198	10232
Sigma-Aldrich	10239
MI	10254
USA	10258
synthetic rat CGRP	10291
No cross-reactivity with other rodent proteins	10311
No cross-reactivity	10311
other rodent proteins	10336
Brejot et al. , 2006	10378
Brejot	10378
et al.	10385
2006	10393
GFP	10400
a polyclonal rabbit antibody -LRB- 1:300 , 240142 , Stratagene , La Jolla CA , USA -RRB- , which was prepared against full-length humanised R. reniformis GFP purified from E. coli	10422
a polyclonal rabbit antibody -LRB- 1:300 , 240142 , Stratagene , La Jolla CA , USA -RRB-	10422
a polyclonal rabbit antibody	10422
1:300 , 240142 , Stratagene , La Jolla CA , USA	10452
1:300	10452
240142	10459
Stratagene	10467
La Jolla CA	10479
USA	10492
full-length humanised R. reniformis GFP purified from E. coli	10525
full-length humanised R. reniformis GFP	10525
E. coli	10579
No cross-reactivity with rodent proteins	10588
No cross-reactivity	10588
rodent proteins	10613
Han et al. , 2006	10648
Han	10648
et al.	10652
2006	10660
the tissue sections	10676
xylene and 100 % ethanol	10712
xylene	10712
100 % ethanol	10723
normotonic phosphate buffered saline -LRB- pH = 7.4 -RRB- containing 0.3 % Triton-X -LRB- Chem Supply , SA , Australia -RRB-	10763
normotonic phosphate	10763
saline -LRB- pH = 7.4 -RRB- containing 0.3 % Triton-X -LRB- Chem Supply , SA , Australia -RRB-	10793
saline -LRB- pH = 7.4 -RRB-	10793
saline	10793
pH	10801
7.4	10804
0.3 % Triton-X	10820
Chem Supply	10835
SA	10848
Australia	10852
a 30 min preincubationwith phosphate	10870
saline-Triton-X solution	10916
10 %	10952
goat serum , the sectionswere incubatedwith the primary antibody for 24 h at 4 °C	10956
goat serum	10956
the sectionswere incubatedwith the primary antibody for 24 h at 4 °C	10968
the sectionswere incubatedwith	10968
the primary antibody for 24 h at 4 °C	10999
the primary antibody	10999
24 h at 4 °C	11024
24 h	11024
4 °C	11032
The sections	11038
phosphate buffered saline and incubated with Alexa Fluor 488-conjugated goat anti-rabbit -LRB- 1:500 ; A11070 , Molecular Probes , Oregon , USA -RRB- or TRITC-conjugated goat anti-rabbit secondary antibody -LRB- 1:200 ; R0156 , Dako , Denmark -RRB- for 2 h at roomtemperature	11071
phosphate	11071
saline	11090
Alexa Fluor 488-conjugated goat anti-rabbit -LRB- 1:500 ; A11070 , Molecular Probes , Oregon , USA -RRB- or TRITC-conjugated goat anti-rabbit secondary antibody -LRB- 1:200 ; R0156 , Dako , Denmark -RRB-	11116
Alexa Fluor 488-conjugated goat anti-rabbit -LRB- 1:500 ; A11070 , Molecular Probes , Oregon , USA -RRB-	11116
Alexa Fluor	11116
488-conjugated goat anti-rabbit -LRB- 1:500 ; A11070 , Molecular Probes , Oregon , USA -RRB-	11128
488-conjugated goat anti-rabbit	11128
1:500	11161
A11070 , Molecular Probes , Oregon , USA	11168
A11070	11168
Molecular Probes	11176
Oregon	11194
USA	11202
TRITC-conjugated goat anti-rabbit secondary antibody -LRB- 1:200 ; R0156 , Dako , Denmark -RRB-	11210
TRITC-conjugated goat	11210
anti-rabbit secondary antibody -LRB- 1:200 ; R0156 , Dako , Denmark -RRB-	11232
anti-rabbit secondary antibody	11232
1:200 ; R0156	11264
1:200	11264
R0156	11271
Dako , Denmark	11278
Dako	11278
Denmark	11284
2 h at roomtemperature	11297
2 h	11297
roomtemperature	11304
the sectionswere counterstainedwith bisbenzimide -LRB- 0.001 % , Hoechst 33258 , Invitrogen Pty. Ltd. , VIC , Australia -RRB- for 20 min ,	11330
the sectionswere counterstainedwith bisbenzimide -LRB- 0.001 % , Hoechst 33258 , Invitrogen Pty. Ltd. , VIC , Australia -RRB-	11330
the sectionswere counterstainedwith bisbenzimide	11330
0.001 % , Hoechst 33258 , Invitrogen Pty. Ltd. , VIC , Australia	11380
0.001 %	11380
Hoechst 33258	11388
Invitrogen Pty. Ltd.	11403
VIC	11425
Australia	11430
20 min	11445
DAKO mounting medium -LRB- DakoCytomation , Dako North America Inc. , CA , USA -RRB-	11477
DAKO mounting medium	11477
DakoCytomation	11499
Dako North America Inc.	11515
CA , USA	11540
No positive labelling	11550
the antibodies	11586
rat liver and spleen tissue -LRB- CGRP antibody specificity tests -RRB- , normal spinal cord -LRB- GFP antibody specificity tests -RRB- or unlabelled spinal cord tissue -LRB- secondary antibody specificity tests -RRB-	11620
rat liver	11620
spleen tissue -LRB- CGRP antibody specificity tests -RRB- , normal spinal cord -LRB- GFP antibody specificity tests -RRB- or unlabelled spinal cord tissue -LRB- secondary antibody specificity tests -RRB-	11634
spleen tissue -LRB- CGRP antibody specificity tests -RRB-	11634
spleen tissue	11634
CGRP antibody specificity tests	11649
normal spinal cord -LRB- GFP antibody specificity tests -RRB-	11683
normal spinal cord	11683
GFP antibody specificity tests	11703
unlabelled spinal cord tissue -LRB- secondary antibody specificity tests -RRB-	11738
unlabelled spinal cord tissue	11738
secondary antibody specificity tests	11769
The tissue	11808
a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	11839
a fluorescent microscope	11839
Olympus BX51 + DP70	11865
Olympus BX51	11865
DP70	11878
2.8	11885
Quantification of the injury size	11890
Quantification	11890
the injury size	11908
The extent of cavity and non-cavity tissue loss rostral and caudal to the transection was measured according to the previously published protocol -LRB- Potas et al. , 2006 -RRB- and using ImageJ software	11924
The extent	11924
cavity and non-cavity tissue loss	11938
rostral and caudal	11972
the transection	11994
the previously published protocol -LRB- Potas et al. , 2006 -RRB-	12036
the previously published protocol	12036
Potas	12071
et al. , 2006	12077
et al.	12077
2006	12085
ImageJ software	12101
Wayne Rasband , National Institutes of Health , USA	12118
Wayne Rasband	12118
National Institutes of Health	12133
National Institutes	12133
Health	12156
USA	12164
each animal	12173
two horizontal sections stained with hematoxylin-eosin , one ventral and one dorsal to the central canal -LRB- 0.5 -- 1 mm apart -RRB- ,	12186
two horizontal sections stained with hematoxylin-eosin	12186
two horizontal sections	12186
hematoxylin-eosin	12223
one ventral and one dorsal to the central canal -LRB- 0.5 -- 1 mm apart -RRB-	12242
one ventral and one dorsal	12242
one	12242
one	12258
the central canal -LRB- 0.5 -- 1 mm apart -RRB-	12272
the central canal	12272
0.5 -- 1 mm apart	12291
0.5	12291
1 mm apart	12295
The rostral area of interest	12323
The rostral area	12323
interest	12343
a line drawn at the rostral border between the intact tissue and the fibrotic scar -LRB- Fig. 1 , line x -RRB- , a parallel line 2 mm further rostral -LRB- Fig. 1 , line y -RRB- ,	12372
a line	12372
the rostral border between the intact tissue and the fibrotic scar -LRB- Fig. 1 , line x -RRB- , a parallel line 2 mm further rostral -LRB- Fig. 1 , line y -RRB- ,	12388
the rostral border	12388
the intact tissue and the fibrotic scar -LRB- Fig. 1 , line x -RRB- , a parallel line 2 mm further rostral -LRB- Fig. 1 , line y -RRB- ,	12415
the intact tissue and the fibrotic scar	12415
the intact tissue	12415
the fibrotic scar	12437
Fig. 1	12456
line x	12464
a parallel line 2 mm further rostral -LRB- Fig. 1 , line y -RRB-	12473
a parallel line 2 mm further rostral	12473
a parallel line	12473
2 mm	12489
further rostral	12494
Fig. 1	12511
line y	12519
two longitudinal lines extrapolated from the lateral edges of the horizontal section at y	12537
two longitudinal lines	12537
the lateral edges of the horizontal section	12578
the lateral edges	12578
the horizontal section	12599
y	12625
a similar approach	12652
the area of interest caudal to the lesion	12672
the area	12672
interest caudal to the lesion	12684
interest caudal	12684
the lesion	12703
Fig. 1 , lines w and z	12727
Fig. 1	12727
lines w and z	12735
lines	12735
w and z	12741
w and	12741
w	12741
Injury within these rostral and caudal areas	12751
Injury	12751
these rostral and caudal areas	12765
these rostral	12765
caudal areas	12783
cavity tissue loss , defined as tissue loss completely bordered by spinal cord tissue , and -LRB- ii -RRB- non-cavity tissue loss ,	12818
cavity tissue loss	12818
tissue	12849
loss completely bordered by spinal cord tissue , and -LRB- ii -RRB- non-cavity tissue loss	12856
loss completely bordered by spinal cord tissue	12856
loss	12856
spinal cord tissue	12884
ii	12909
non-cavity tissue loss	12913
fibrosis or shrinkage of the cord edges	12948
fibrosis or shrinkage	12948
the cord edges	12973
both instances	12992
the extent of injury	13008
the extent	13008
injury	13022
the average of the measurements in the 2 horizontal sections per animal , expressed as a percentage of the total rostral or caudal area of interest	13033
the average	13033
the measurements in the 2 horizontal sections per animal , expressed as a percentage of the total rostral or caudal area of interest	13048
the measurements	13048
the 2 horizontal sections per animal	13068
the 2 horizontal sections	13068
animal	13098
a percentage of the total rostral or caudal area of interest	13119
a percentage of the total rostral	13119
a percentage	13119
the total rostral	13135
caudal area of interest	13156
caudal area	13156
interest	13171
2.9	13181
Morphometric analysis of sympathetic preganglionic neurons	13186
Morphometric analysis	13186
sympathetic preganglionic neurons	13211
Morphological features of sympathetic preganglionic neurons in the injured and intact spinal cords were analysed as described previously	13245
Morphological features	13245
sympathetic preganglionic neurons in the injured and intact spinal cords	13271
sympathetic preganglionic neurons	13271
the injured and intact spinal cords	13308
Kalincik et al. , 2010	13383
Kalincik	13383
et al.	13392
2010	13400
each animal , 2	13410
each animal	13410
2	13423
3 horizontal sections through the intermediolateral column	13425
3 horizontal sections	13425
the intermediolateral column	13455
and 9 -- 10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	13498
and 9	13498
10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	13505
10 neurons located rostral -LRB- T2 -- T3 -RRB-	13505
10 neurons located rostral	13505
10 neurons	13505
T2 -- T3	13533
T2	13533
T3	13536
9	13544
10 neurons located caudal -LRB- T5 -- T6 -RRB- to the injury	13546
10 neurons located caudal -LRB- T5 -- T6 -RRB-	13546
10 neurons located caudal	13546
10 neurons	13546
T5 -- T6	13573
T5	13573
T6	13576
the injury	13583
ImageJ software	13614
The morphometric features of each cell	13631
The morphometric features	13631
each cell	13660
one 35 μm thick horizontal section	13691
one 35 μm	13691
Only cells with clearly distinguishable perikarya and dendritic trees	13727
Only cells	13727
clearly distinguishable perikarya and dendritic trees	13743
clearly distinguishable perikarya	13743
dendritic trees	13781
The examined neurons	13812
the criteria of lying within the nucleus intermediolateralis pars principalis and pars funicularis and being within 2 segments from the injury site	13843
the criteria	13843
the nucleus intermediolateralis pars principalis and pars funicularis	13872
2 segments	13959
the injury site	13975
both left and right intermediolateral columns -LRB- Fig. 2 -RRB-	14022
both left and right intermediolateral columns	14022
Fig. 2	14069
Three morphological features were recorded : -LRB- i -RRB- cross-sectional area of soma , -LRB- ii -RRB- overall length of all visible processes and -LRB- iii -RRB- number of primary dendrites .	14078
Three morphological features were recorded	14078
Three morphological features	14078
-LRB- i -RRB- cross-sectional area of soma , -LRB- ii -RRB- overall length of all visible processes and -LRB- iii -RRB- number of primary dendrites	14122
-LRB- i -RRB- cross-sectional area	14122
i	14123
soma , -LRB- ii -RRB- overall length of all visible processes and -LRB- iii -RRB- number of primary dendrites	14150
soma	14150
-LRB- ii -RRB- overall length of all visible processes	14156
-LRB- ii -RRB- overall length	14156
ii	14157
all visible processes	14179
iii	14206
number of primary dendrites	14211
number	14211
primary dendrites	14221
The morphological features	14240
OEC-treated , control and intact animals	14289
control	14302
2.10	14330
Quantification of the primary afferent fibre density The analysis of the density of primary afferent fibres stained for CGRP	14336
Quantification	14336
the primary afferent fibre density The analysis of the density of primary afferent fibres stained for CGRP	14354
the primary afferent fibre density	14354
The analysis of the density of primary afferent fibres	14389
The analysis	14389
the density of primary afferent fibres	14405
the density	14405
primary afferent fibres	14420
CGRP	14456
transverse sections	14478
T1 and T7	14503
ImageJ software	14519
laminae	14542
the help of the atlas of rat	14571
the help	14571
the atlas of rat	14583
the atlas	14583
rat	14596
spinal cord anatomy -LRB- Watson et al. , 2008 -RRB-	14600
spinal cord anatomy	14600
Watson	14621
et al. , 2008	14628
et al.	14628
2008	14636
Signal intensity of the background from each of the CGRP immunoreacted sections	14643
Signal intensity	14643
the background from each of the CGRP immunoreacted sections	14663
the background	14663
each of the CGRP immunoreacted sections	14683
each	14683
the CGRP immunoreacted sections	14691
a 10,000 μm2 square selection	14743
the lamina VII	14776
This	14792
each image	14817
the images	14832
uniform criteria -LRB- Fig. 3 -RRB-	14871
uniform criteria	14871
Fig. 3	14889
A grid with circular selections -LRB- area : 1000 μm2 each -RRB-	14898
A grid with circular selections	14898
A grid	14898
circular selections	14910
area : 1000 μm2 each	14931
area	14931
1000 μm2 each	14937
1000 μm2	14937
each	14946
laminae I -- V ,	14974
laminae I	14974
laminae	14974
I	14982
V	14984
5 selections per lamina	14994
5 selections	14994
lamina	15011
The percentage of CGRP positivity within each of the five areas per lamina	15019
The percentage	15019
CGRP positivity within each of the five areas per lamina	15037
CGRP positivity	15037
each of the five areas per lamina	15060
each	15060
the five areas per lamina	15068
the five areas	15068
lamina	15087
The measurements	15108
lamina and animal	15143
2.11	15162
Data at 9 weeks post-injury In addition to the experiments carried out in the intact animals -LRB- n = 6 -RRB- and those with SCI -LRB- n = 24 -RRB- included in this study -LRB- 1 and 4 weeks post-injury -RRB- , data describing the extent of cavity and noncavity tissue loss and the morphometric features of SPNs from our previous experiments at 9 weeks post-injury	15168
Data	15168
9 weeks post-injury In addition to the experiments carried out in the intact animals -LRB- n = 6 -RRB- and those with SCI -LRB- n = 24 -RRB- included in this study -LRB- 1 and 4 weeks post-injury -RRB- , data describing the extent of cavity and noncavity tissue loss and the morphometric features of SPNs from our previous experiments at 9 weeks post-injury	15176
9 weeks post-injury In addition to the experiments carried out in the intact animals -LRB- n = 6 -RRB-	15176
9 weeks	15176
post-injury	15184
addition to the experiments	15199
addition	15199
the experiments	15211
the intact animals	15242
n	15262
6	15264
those with SCI -LRB- n = 24 -RRB- included in this study -LRB- 1 and 4 weeks post-injury -RRB-	15271
those with SCI -LRB- n = 24 -RRB- included in this study	15271
those	15271
SCI -LRB- n = 24 -RRB- included in this study	15282
SCI	15282
n	15287
24	15289
this study	15305
1 and 4 weeks	15317
data describing the extent of cavity and noncavity tissue loss and the morphometric features of SPNs from our previous experiments at 9 weeks post-injury	15345
data	15345
the extent of cavity and noncavity tissue loss and the morphometric features of SPNs from our previous experiments	15361
the extent of cavity and noncavity tissue loss	15361
the extent	15361
cavity and noncavity tissue loss	15375
the morphometric features of SPNs from our previous experiments	15412
the morphometric features	15412
SPNs from our previous experiments	15441
SPNs	15441
our previous experiments	15451
9 weeks	15479
the present manuscript -LRB- Kalincik et al. , 2010 -RRB-	15521
the present manuscript	15521
Kalincik	15545
et al. , 2010	15554
et al.	15554
2010	15562
This	15569
order	15586
a comparison of the early changes	15601
a comparison	15601
the early changes	15617
those seen at longer survival times	15640
those	15640
longer survival times	15654
The animals from the previous study -LRB- n = 13 -RRB-	15677
The animals	15677
the previous study -LRB- n = 13 -RRB-	15694
the previous study	15694
n	15714
13	15716
the same surgeon	15737
protocols identical to those used here	15763
protocols	15763
those used here	15786
those	15786
The data describing the morphometric features of SPNs	15803
The data	15803
the morphometric features of SPNs	15823
the morphometric features	15823
SPNs	15852
the data describing the injury size at 9 weeks post-injury	15895
the data	15895
the injury size	15915
9 weeks	15934
Quantification of the primary afferent fibre density	15965
Quantification	15965
the primary afferent fibre density	15983
animals at 9 weeks post	16041
animals	16041
9 weeks post	16052
SCI , as segments T1 and T7 were not collected	16066
SCI	16066
segments T1 and T7	16074
segments T1	16074
T7	16090
2.12	16113
Statistical analysis All measurements were carried out by a researcher	16119
Statistical analysis	16119
All measurements	16140
a researcher	16177
the treatment	16201
Data	16216
mean ± SEM	16249
Software package SPSS 17.0 for Windows -LRB- SPSS Inc. , Illinois , USA -RRB-	16259
Software package SPSS 17.0 for Windows	16259
Software package SPSS	16259
17.0 for Windows	16281
17.0	16281
Windows	16290
SPSS Inc.	16299
Illinois	16310
USA	16320
all statistical analyses	16338
Effects	16364
p	16403
≤ 0.05	16404
A three-way analysis of variance -LRB- ANOVA -RRB-	16411
A three-way analysis of variance	16411
A three-way analysis	16411
variance	16435
ANOVA	16445
cavity tissue loss , non-cavity tissue loss and CGRP density	16472
cavity tissue loss	16472
non-cavity tissue loss	16492
CGRP density	16519
the selected laminae with respect to Treatment -LRB- OEC-treated vs. control groups -RRB- , Position -LRB- rostral vs. caudal to the SCI -RRB- and Time following the cord transection -LRB- intact vs. week 1 vs. week 4 vs. week 9 post-injury -RRB-	16535
the selected laminae with respect to Treatment -LRB- OEC-treated vs. control groups -RRB-	16535
the selected laminae	16535
respect	16561
Treatment -LRB- OEC-treated vs. control groups -RRB-	16572
Treatment	16572
OEC-treated vs. control groups	16583
OEC-treated	16583
control groups	16599
Position -LRB- rostral vs. caudal to the SCI -RRB-	16616
Position	16616
rostral vs. caudal to the SCI	16626
rostral	16626
caudal to the SCI	16638
caudal	16638
the SCI	16648
Time following the cord transection -LRB- intact vs. week 1 vs. week 4 vs. week 9 post-injury -RRB-	16661
Time	16661
the cord transection -LRB- intact vs. week 1 vs. week 4 vs. week 9 post-injury -RRB-	16676
the cord transection	16676
intact vs. week	16698
1 vs. week 4 vs. week 9 post-injury	16714
1	16714
week 4 vs. week	16720
week 4	16720
week	16731
Cavity and non-cavity tissue loss at week 9 post-SCI in the OECtreated vs. control rats and rostral vs. caudal to the lesion	16752
Cavity and non-cavity tissue loss	16752
week 9 post-SCI in the OECtreated vs. control rats and rostral vs. caudal to the lesion	16789
week 9 post-SCI in the OECtreated vs. control rats	16789
week 9 post-SCI	16789
the OECtreated vs. control rats	16808
rostral vs. caudal to the lesion	16844
rostral	16844
caudal to the lesion	16856
caudal	16856
the lesion	16866
a two-way ANOVA	16896
Linear association between cavity tissue loss and non-cavity tissue loss	16913
Linear association	16913
cavity tissue loss and non-cavity tissue loss	16940
cavity tissue loss	16940
non-cavity tissue loss	16963
a linear regression analysis	17004
Comparison of morphometric features of the SPNs with respect to Treatment , Position and Time post-injury	17034
Comparison	17034
morphometric features of the SPNs with respect to Treatment , Position and Time post-injury	17048
morphometric features	17048
the SPNs with respect to Treatment , Position and Time post-injury	17073
the SPNs	17073
respect to Treatment , Position and Time post-injury	17087
respect	17087
Treatment , Position and Time post-injury	17098
Treatment	17098
Position	17109
Time post-injury	17122
Time	17122
post-injury	17127
a linear mixed model -LRB- MIXED , SPSS 17.0 -RRB-	17160
a linear mixed model	17160
MIXED	17182
SPSS 17.0	17189
restricted maximum likelihood algorithm	17207
fixed and random effects -LRB- Kalincik et al. , 2010 -RRB-	17259
fixed and random effects	17259
Kalincik	17285
et al. , 2010	17294
et al.	17294
2010	17302
The effects of Treatment , Position and Time post-injury	17309
The effects	17309
Treatment , Position and Time post-injury	17324
Treatment	17324
Position	17335
Time post-injury	17348
Time	17348
post-injury	17353
the subject effect	17391
The model	17433
full factorial interaction terms and residual terms -LRB- global and subject -RRB-	17465
full factorial interaction terms	17465
residual terms -LRB- global and subject -RRB-	17502
residual terms	17502
Constant correlation	17539
all pairs of measurements on the same animal	17576
all pairs	17576
measurements on the same animal	17589
measurements	17589
the same animal	17605
all analyses	17625
post-hoc comparisons	17639
Tukey 's tests -LRB- effect of Time post-injury -RRB- and unpaired t-tests -LRB- Position and Treatment effects -RRB-	17682
Tukey 's tests -LRB- effect of Time post-injury -RRB-	17682
Tukey 's tests	17682
Tukey 's	17682
effect of Time post-injury	17697
effect	17697
Time post-injury	17707
unpaired t-tests -LRB- Position and Treatment effects -RRB-	17729
unpaired t-tests	17729
Position and Treatment effects	17747
Position	17747
Treatment effects	17760
Results	17784
1	17797
Longitudinal section through the T4 transection with an illustration of the areas of interest for the purpose of measurement of cavity tissue loss -LRB- C -RRB- and non-cavity tissue loss -LRB- NC -RRB- .	17800
Longitudinal section	17800
the T4 transection with an illustration of the areas of interest	17829
the T4 transection	17829
an illustration of the areas of interest	17853
an illustration	17853
the areas of interest	17872
the areas	17872
interest	17885
the purpose of measurement	17898
the purpose	17898
measurement	17913
cavity tissue loss -LRB- C -RRB- and non-cavity tissue loss -LRB- NC -RRB-	17928
cavity tissue loss	17928
C	17948
non-cavity tissue loss	17955
NC	17979
The areas of interest	17984
The areas	17984
interest	17997
the lines drawn at the border between the intact tissue and the fibrotic scar -LRB- x , rostral ; w , caudal -RRB- and by the parallel lines drawn 2 mm rostrally -LRB- y -RRB- or caudally -LRB- z -RRB- to the previous lines	18025
the lines	18025
the border between the intact tissue and the fibrotic scar -LRB- x , rostral ; w , caudal -RRB- and by the parallel lines drawn 2 mm rostrally -LRB- y -RRB- or caudally -LRB- z -RRB- to the previous lines	18044
the border between the intact tissue and the fibrotic scar -LRB- x , rostral ; w , caudal -RRB- and by the parallel lines drawn 2 mm rostrally -LRB- y -RRB- or caudally -LRB- z -RRB-	18044
the border between the intact tissue and the fibrotic scar -LRB- x , rostral ; w , caudal -RRB- and by the parallel lines drawn 2 mm rostrally -LRB- y -RRB- or caudally	18044
the border	18044
the intact tissue and the fibrotic scar -LRB- x , rostral ; w , caudal -RRB- and by the parallel lines	18063
the intact tissue and the fibrotic scar -LRB- x , rostral ; w , caudal -RRB-	18063
the intact tissue	18063
the fibrotic scar -LRB- x , rostral ; w , caudal -RRB-	18085
the fibrotic scar	18085
x , rostral ; w , caudal	18104
x	18104
rostral ; w	18107
rostral	18107
w	18116
caudal	18119
the parallel	18134
2 mm rostrally -LRB- y -RRB-	18159
2 mm rostrally	18159
2 mm	18159
y	18175
the previous lines	18197
Lateral borders of the areas	18217
Lateral borders	18217
the areas	18236
parallel lines drawn from the lateral edges of lines y	18262
parallel lines	18262
the lateral edges of lines y	18288
the lateral edges	18288
lines y	18309
the lesion	18344
lines	18363
x	18369
Fig. 2	18378
Examples of sympathetic preganglionic neurons and their measured morphometric features .	18386
Examples	18386
sympathetic preganglionic neurons and their measured morphometric features	18398
sympathetic preganglionic neurons	18398
their measured morphometric features	18436
A , longitudinal section through an injured spinal cord	18474
, longitudinal section through an injured spinal cord	18475
, longitudinal section	18475
an injured spinal cord	18506
NADPHdiaphorase	18541
Sympathetic preganglionic neurons in the intermediolateral columns -LRB- IML , arrowheads -RRB-	18558
Sympathetic preganglionic neurons	18558
the intermediolateral columns -LRB- IML , arrowheads -RRB-	18595
the intermediolateral columns	18595
IML	18626
arrowheads	18631
the lateral aspects of the grey matter rostral and Fig. 3	18659
the lateral aspects	18659
the grey matter rostral and Fig. 3	18682
the grey matter rostral	18682
Fig. 3	18711
Example of the CGRP density measurement .	18719
Example	18719
the CGRP density measurement	18730
Background signal intensity recorded in Rexed lamina VII -LRB- white squares -RRB-	18760
Background signal intensity	18760
Rexed lamina VII	18800
white squares	18818
the image	18853
the area of the CGRP positivity	18867
the area	18867
the CGRP positivity	18879
5 selections per lamina -LRB- circles -RRB- superimposed as a grid over the section	18915
5 selections	18915
lamina -LRB- circles -RRB- superimposed as a grid over the section	18932
lamina	18932
circles	18940
a grid over the section	18965
a grid	18965
the section	18977
Laminae I -- V were assessed .	18990
Laminae I	18990
Laminae	18990
I	18998
V were assessed	19000
V	19000
I -- VII , Rexed laminae ; CC , central canal ; D , dorsal nucleus ; ICL , intercalated nucleus ; IML , intermediolateral nucleus ; IMM , intermediomedial nucleus .	19017
I	19017
VII , Rexed laminae	19019
VII	19019
Rexed laminae	19024
CC , central canal	19039
CC	19039
central canal	19043
D , dorsal nucleus	19058
D	19058
dorsal nucleus	19061
ICL , intercalated nucleus	19077
ICL	19077
intercalated nucleus	19082
IML , intermediolateral nucleus	19104
IML	19104
intermediolateral nucleus	19109
IMM , intermediomedial nucleus	19136
IMM	19136
intermediomedial nucleus	19141
Fig. 4 .	19168
Fig.	19168
4	19173
Cavity and non-cavity tissue loss .	19176
Cavity and non-cavity tissue	19176
loss	19205
Increase in the extent of cavity tissue loss with Time post-injury	19211
Increase	19211
the extent of cavity tissue loss with Time post-injury	19223
the extent	19223
cavity tissue loss with Time post-injury	19237
cavity tissue loss	19237
Time post-injury	19261
apparent rostral and caudal	19282
the transection in both groups -LRB- pb0 .001 , three-way ANOVA -RRB-	19313
the transection	19313
both groups -LRB- pb0 .001 , three-way ANOVA -RRB-	19332
both groups	19332
pb0 .001 , three-way ANOVA	19345
pb0 .001	19345
three-way ANOVA	19354
The effect of Treatment	19372
The effect	19372
Treatment	19386
week 9 when analysed separately -LRB- p = 0.05 , two-way ANOVA -RRB-	19412
week 9	19412
p = 0.05 , two-way ANOVA	19445
p = 0.05	19445
p	19445
0.05	19447
two-way ANOVA	19453
≤ 0.05 -LRB- vs. week 1 -RRB- ; † , p ≤ 0.05 -LRB- vs. week 4 -RRB- , Tukey test -LRB- post-hoc -RRB-	19473
≤	19473
0.05 -LRB- vs. week 1 -RRB- ; † , p ≤ 0.05 -LRB- vs. week 4 -RRB-	19474
0.05	19474
week 1	19484
† , p ≤ 0.05 -LRB- vs. week 4 -RRB-	19493
†	19493
p ≤ 0.05 -LRB- vs. week 4 -RRB-	19496
p	19496
≤ 0.05 -LRB- vs. week 4 -RRB-	19497
≤ 0.05	19497
week 4	19508
Tukey test -LRB- post-hoc -RRB-	19517
Tukey test	19517
Fig. 5 .	19541
Fig.	19541
5	19546
Morphometric features of the SPNs at segments T2 -- 3 and T5 -- 6 in the intact rats -LRB- int -RRB- and in the rats at 1 week -LRB- w1 -RRB- , 4 weeks -LRB- w4 -RRB- and 9 weeks -LRB- w9 -RRB- post-injury .	19549
Morphometric features of the SPNs at segments T2	19549
Morphometric features	19549
the SPNs at segments T2	19574
the SPNs	19574
segments T2	19586
3 and T5	19598
3	19598
T5	19604
6 in the intact rats -LRB- int -RRB- and in the rats at 1 week -LRB- w1 -RRB- , 4 weeks -LRB- w4 -RRB- and 9 weeks -LRB- w9 -RRB- post-injury	19607
6	19607
the intact rats -LRB- int -RRB-	19612
the intact rats	19612
int	19629
the rats at 1 week -LRB- w1 -RRB- , 4 weeks -LRB- w4 -RRB- and 9 weeks -LRB- w9 -RRB-	19641
the rats	19641
1 week -LRB- w1 -RRB- , 4 weeks -LRB- w4 -RRB- and 9 weeks -LRB- w9 -RRB-	19653
1 week -LRB- w1 -RRB-	19653
1 week	19653
w1	19661
4 weeks -LRB- w4 -RRB-	19666
w4	19675
9 weeks -LRB- w9 -RRB-	19683
w9	19692
post-injury	19696
Significant interactions between Position -LRB- T2 -- 3 , T5 -- 6 -RRB- , Treatment -LRB- control , OECtreated -RRB- and Time post-injury -LRB- int , w1 , w4 and w9 -RRB-	19709
Significant interactions between Position -LRB- T2 -- 3 , T5 -- 6 -RRB- , Treatment -LRB- control , OECtreated -RRB-	19709
Significant interactions between Position -LRB- T2 -- 3 , T5 -- 6 -RRB-	19709
Significant interactions	19709
Position -LRB- T2 -- 3 , T5 -- 6 -RRB-	19742
Position	19742
T2 -- 3	19752
T2	19752
3	19755
T5 -- 6	19758
T5	19758
6	19761
Treatment -LRB- control , OECtreated -RRB-	19765
Treatment	19765
control , OECtreated	19776
control	19776
Time post-injury -LRB- int , w1 , w4 and w9 -RRB-	19801
Time	19801
post-injury -LRB- int , w1 , w4 and w9 -RRB-	19806
post-injury	19806
int , w1 , w4 and w9	19819
int	19819
w1 , w4 and w9	19824
all three analysed features -LRB- pb0 .03 , linear mixed model -RRB-	19853
all three analysed features	19853
pb0 .03	19882
linear mixed model	19890
Treatment , p ≤ 0.05 , t-test -LRB- post-hoc -RRB-	19924
Treatment , p ≤ 0.05 ,	19924
Treatment	19924
p ≤ 0.05	19935
p	19935
≤ 0.05	19936
Fig. 6 .	19963
Fig.	19963
6	19968
Density of the CGRP-labelled primary afferent fibres within laminae I -- V of the dorsal horns at T1 and T7 .	19971
Density of the CGRP-labelled primary afferent fibres within laminae I	19971
Density of the CGRP-labelled primary afferent fibres within laminae	19971
Density	19971
the CGRP-labelled primary afferent fibres within laminae	19982
the CGRP-labelled primary afferent fibres	19982
laminae	20031
I	20039
V of the dorsal horns at T1 and T7	20041
V	20041
the dorsal horns at T1 and T7	20046
the dorsal horns	20046
T1 and T7	20066
A significant effect of Time post-injury	20077
A significant effect	20077
Time post-injury	20101
lamina II -LRB- p = 0.04 , three-way ANOVA -RRB-	20131
lamina II	20131
p = 0.04 , three-way ANOVA	20142
p = 0.04	20142
p	20142
0.04	20144
three-way ANOVA	20150
* , p ≤ 0.05 -LRB- vs. week 1 -RRB- , Tukey 's test -LRB- post-hoc -RRB- .	20168
*	20168
p ≤ 0.05 -LRB- vs. week 1 -RRB-	20171
p	20171
≤ 0.05 -LRB- vs. week 1 -RRB-	20172
≤ 0.05	20172
week 1	20183
Tukey 's test -LRB- post-hoc -RRB-	20192
Tukey 's test	20192
Tukey 's	20192
our lab	20244
OECs transplanted into the transection site within a Gelfoam block	20253
OECs	20253
the transection site	20276
a Gelfoam block	20304
the transplant	20341
week 1	20359
4 weeks post-injury -LRB- Kalincik et al. , 2010 -RRB-	20390
4 weeks post-injury	20390
Kalincik	20411
et al. , 2010	20420
et al.	20420
2010	20428
3.1	20435
Injury size	20440
the T4 transection	20462
we	20482
a formation of intraspinal cavities and an overall decrease	20494
a formation	20494
intraspinal cavities and an overall decrease	20509
intraspinal cavities	20509
an overall decrease	20534
the volume of the nervous tissue in both rostral and caudal stumps of the injured spinal cord -LRB- Fig. 1 -RRB-	20557
the volume	20557
the nervous tissue in both rostral and caudal stumps of the injured spinal cord -LRB- Fig. 1 -RRB-	20571
the nervous tissue	20571
both rostral and caudal stumps	20593
rostral	20598
caudal stumps	20610
the injured spinal cord -LRB- Fig. 1 -RRB-	20627
the injured spinal cord	20627
Fig. 1	20652
It	20661
Fig. 4	20681
the extent of cavities in both OEC and control groups	20693
the extent	20693
cavities in both OEC and control groups	20707
cavities	20707
both OEC and control groups	20719
OEC	20724
control groups	20732
time postinjury	20772
the segments rostral and caudal	20791
the SCI	20826
Cavities	20835
only about 5 % of the rostral and caudal stumps	20853
only about 5 %	20853
the rostral and caudal stumps	20870
the rostral	20870
caudal stumps	20886
week 1	20903
10 % by week 4	20925
10 %	20925
week 4	20932
over 20 %	20946
week 9	20958
This increase	20966
the level of statistical significance -LRB- pb0 .001 , F2 ,34 = 23.3 , three-way ANOVA -RRB-	20988
the level	20988
statistical significance -LRB- pb0 .001 , F2 ,34 = 23.3 , three-way ANOVA -RRB-	21001
statistical significance	21001
pb0 .001 , F2 ,34 = 23.3 , three-way ANOVA	21027
pb0 .001	21027
F2 ,34 = 23.3	21036
F2 ,34	21036
= 23.3	21041
three-way ANOVA	21048
all time-points -LRB- pb0 .03 , t5N2 .5 , posthoc Tukey 's tests -RRB-	21085
all time-points	21085
pb0 .03 , t5N2 .5 , posthoc Tukey 's tests	21102
pb0 .03	21102
t5N2 .5 , posthoc Tukey 's tests	21110
t5N2 .5	21110
posthoc Tukey 's tests	21118
posthoc Tukey 's	21118
The change in cavity size	21142
The change	21142
cavity size	21156
segments rostral and caudal	21183
segments	21183
the lesion -LRB- p = 1 , F2 ,34 = 0.02 , three-way ANOVA -RRB-	21214
the lesion	21214
p = 1 , F2 ,34 = 0.02 , three-way ANOVA	21226
p = 1	21226
p	21226
1	21228
F2 ,34 = 0.02	21231
F2 ,34	21231
0.02	21237
three-way ANOVA	21243
three-way	21243
ANOVA	21253
non-cavity tissue loss	21265
no clear trend	21289
rostral or caudal	21320
the lesion -LRB- pN0 .2 , F2 ,34 b1 .6 , three-way ANOVA -RRB-	21341
the lesion	21341
pN0 .2 , F2 ,34 b1 .6 , three-way ANOVA	21353
pN0 .2	21353
F2 ,34 b1 .6	21360
F2 ,34	21360
b1 .6	21365
three-way ANOVA	21371
all times	21392
non-cavity tissue loss	21402
10 % of the delineated rostral and caudal areas	21443
10 %	21443
the delineated rostral and caudal areas	21450
the	21450
rostral and caudal areas	21465
rostral	21465
caudal areas	21477
Fig. 4	21509
the OEC-treated animals	21520
there	21544
a slower increase	21554
cavitation compared to the control animals	21575
cavitation	21575
the control animals	21598
this trend	21628
statistical significance -LRB- p = 0.07 , F2 ,34 = 2.8 , three-way ANOVA -RRB-	21653
statistical significance	21653
p = 0.07 , F2 ,34 = 2.8 , three-way ANOVA	21679
p = 0.07	21679
p	21679
0.07	21681
F2 ,34 = 2.8	21687
F2 ,34	21687
2.8	21693
three-way ANOVA	21698
three-way	21698
ANOVA	21708
cavity tissue loss between the OEC-treated and the control groups at week 9	21746
cavity tissue loss between the OEC-treated	21746
cavity tissue loss	21746
the OEC-treated	21773
the control groups at week 9	21793
the control groups	21793
week 9	21815
the effect of Treatment	21834
the effect	21834
Treatment	21848
p = 0.05 , F1 ,11 = 4.3 , two-way ANOVA	21889
p = 0.05	21889
p	21889
0.05	21891
F1 ,11 = 4.3	21897
F1 ,11	21897
4.3	21903
two-way ANOVA	21908
two-way	21908
ANOVA	21916
contrast	21927
no consistent trends in the non-cavity tissue loss	21937
no consistent trends	21937
the non-cavity tissue loss	21961
the OEC transplantation were seen -LRB- p ≥ 0.3 , F2 ,34 ≤ 1.2 , three-way ANOVA -RRB-	22001
the OEC transplantation were seen	22001
the OEC transplantation	22001
p ≥	22036
0.3 , F2 ,34 ≤ 1.2 , three-way ANOVA	22038
0.3	22038
F2 ,34 ≤ 1.2	22043
F2 ,34	22043
≤ 1.2	22048
three-way ANOVA	22054
the data	22092
week 9 separately -LRB- p = 0.6 , F1 ,11 = 0.3 , two-way ANOVA -RRB-	22104
week 9 separately	22104
week 9	22104
p = 0.6 , F1 ,11 = 0.3 , two-way ANOVA	22123
p = 0.6	22123
p	22123
0.6	22125
F1 ,11 = 0.3	22130
F1 ,11	22130
0.3	22136
two-way ANOVA	22141
two-way	22141
ANOVA	22149
The association between cavity and non-cavity tissue loss	22157
The association	22157
cavity and non-cavity tissue loss	22181
The relation between the two variables	22229
The relation	22229
the two variables	22250
a linear regression analysis -LRB- R2 = 10 − 6 ; p = 0.99 -RRB-	22294
a linear regression analysis	22294
R2 = 10 − 6 ; p = 0.99	22324
R2	22324
= 10 − 6 ; p = 0.99	22326
= 10 − 6	22326
= 10	22326
6	22330
p = 0.99	22333
p	22333
0.99	22335
3.2	22342
Morphometric features of SPNs The effect of injury on SPN morphology	22347
Morphometric features	22347
SPNs The effect of injury on SPN morphology	22372
SPNs	22372
The effect of injury on SPN morphology	22377
The effect	22377
injury on SPN morphology	22391
injury	22391
SPN morphology	22401
the values recorded in the intact and the control groups -LRB- Fig. 5 -RRB-	22443
the values	22443
the intact and the control groups -LRB- Fig. 5 -RRB-	22466
the intact and the control groups	22466
the control	22481
Fig. 5	22501
Injury	22510
an increase	22524
soma size rostral and caudal	22539
soma size rostral	22539
caudal	22561
the lesion -LRB- pb0 .001 , F3 ,21 = 4.2 , linear mixed model -RRB-	22571
the lesion	22571
pb0 .001 , F3 ,21 = 4.2 , linear mixed model	22583
pb0 .001	22583
F3 ,21 = 4.2	22592
F3 ,21	22592
4.2	22598
linear mixed model	22603
This increase	22624
the 9 weeks following transection	22696
the 9 weeks	22696
transection	22718
Overall dendritic length of the examined SPNs	22731
Overall dendritic length	22731
the examined SPNs	22759
a similar trend	22784
SCI	22818
the increase	22833
soma size	22898
the increase in dendritic lengthwas only temporary -LRB- i.e. apparent at weeks 1 and 4 -RRB- with values at week 9 post-injury	22909
the increase	22909
dendritic lengthwas only temporary -LRB- i.e. apparent at weeks 1 and 4 -RRB- with values at week 9 post-injury	22925
dendritic lengthwas	22925
weeks 1 and 4	22978
values at week 9 post-injury	22998
values	22998
week 9 post-injury	23008
week	23008
those in the intact animals	23038
those	23038
the intact animals	23047
The statistical analysis	23067
a significant effect of Time post-injury -LRB- p = 0.004 , F3 ,21 = 2.1 , linear mixed model -RRB- , specifically at weeks 1 and 4 vs. week 9 in the SPNs rostral	23102
a significant effect of Time post-injury -LRB- p = 0.004 , F3 ,21 = 2.1 , linear mixed model -RRB- , specifically at weeks 1 and 4	23102
a significant effect of Time post-injury	23102
a significant effect	23102
Time post-injury	23126
p	23144
= 0.004 , F3 ,21 = 2.1 , linear mixed model	23145
= 0.004	23145
F3 ,21 = 2.1	23153
F3 ,21	23153
2.1	23159
linear mixed model	23164
weeks 1 and 4	23201
week 9 in the SPNs rostral	23219
week 9	23219
the SPNs rostral	23229
the lesion -LRB- p ≤ 0.01 , t55 ≥ 2.4 , post-hoc Tukey 's tests -RRB-	23249
the lesion	23249
p ≤ 0.01 , t55 ≥ 2.4 , post-hoc Tukey 's tests	23261
p ≤ 0.01	23261
p	23261
≤ 0.01	23262
t55 ≥ 2.4	23269
t55	23269
≥ 2.4	23272
post-hoc Tukey 's tests	23278
post-hoc	23278
Tukey 's tests	23287
Tukey 's	23287
dendritic length	23314
SCI	23332
a temporary increase	23346
the number of primary dendrites of the rostral and caudal SPNs , which resolved at 9 weeks post-injury -LRB- pb0 .001 , F3 ,21 = 8.8 , linear mixed model -RRB-	23370
the number	23370
primary dendrites of the rostral and caudal SPNs	23384
primary dendrites	23384
the rostral and caudal SPNs	23405
the rostral	23405
caudal SPNs	23421
9 weeks post-injury -LRB- pb0 .001 , F3 ,21 = 8.8 , linear mixed model -RRB-	23452
9 weeks post-injury	23452
pb0 .001 , F3 ,21 = 8.8 , linear mixed model	23473
pb0 .001	23473
F3 ,21 = 8.8	23482
F3 ,21	23482
8.8	23488
linear mixed model	23493
the effect ofOEC transplantation	23526
morphometric features of SPNs in the OEC-treated rats	23559
morphometric features	23559
SPNs in the OEC-treated rats	23584
SPNs	23584
the OEC-treated rats	23592
those in the control groups -LRB- Fig. 5 -RRB-	23630
those	23630
the control groups -LRB- Fig. 5 -RRB-	23639
the control groups	23639
Fig. 5	23659
soma size of the rostral SPNs	23674
soma size	23674
the rostral SPNs	23687
the groups	23727
somata of the caudal SPNs in the OEC-treated animals	23739
somata	23739
the caudal SPNs in the OEC-treated animals	23749
the caudal SPNs	23749
the OEC-treated animals	23768
week 9 post-injury	23808
These observations	23828
the linear mixed model analysis , which showed a significant interaction effect of Treatment × Time post-injury × Position -LRB- p = 0.04 , F2 ,786 = 3.7 -RRB-	23867
the linear mixed model analysis	23867
a significant interaction effect of Treatment × Time post-injury × Position -LRB- p = 0.04 , F2 ,786 = 3.7 -RRB-	23913
a significant interaction effect	23913
Treatment × Time post-injury × Position -LRB- p = 0.04 , F2 ,786 = 3.7 -RRB-	23949
Treatment × Time post-injury × Position	23949
Treatment × Time	23949
× Position	23975
p = 0.04 , F2 ,786 = 3.7	23986
p	23986
= 0.04 , F2 ,786 = 3.7	23987
= 0.04	23987
F2 ,786 = 3.7	23994
F2 ,786	23994
3.7	24001
Post-hoc analysis	24007
a significant effect of Treatment	24031
a significant effect	24031
Treatment	24055
the caudal SPNs atweek 9 post-injury -LRB- p = 0.02 , t59 = 2.1 , t-test -RRB-	24068
the caudal SPNs atweek 9 post-injury	24068
the caudal SPNs	24068
p	24106
= 0.02 , t59 = 2.1 , t-test	24107
= 0.02	24107
t59 = 2.1	24114
t59	24114
2.1	24118
t-test	24123
the other time-points -LRB- p ≥ 0.2 , t54 ≤ 0.8 , t-tests -RRB-	24142
the other time-points	24142
p ≥	24165
0.2 , t54 ≤ 0.8 , t-tests	24167
0.2	24167
t54 ≤ 0.8	24172
t54	24172
≤ 0.8	24175
t-tests	24181
Overall dendritic length of the rostral SPNs in the OEC-treated groups	24190
Overall dendritic length	24190
the rostral SPNs in the OEC-treated groups	24218
the rostral SPNs	24218
the OEC-treated groups	24238
the dendritic lengths in the control groups at all time-points	24270
the dendritic lengths	24270
the control groups at all time-points	24295
the control groups	24295
all time-points	24317
Caudal to the lesion , a similar trend	24346
Caudal	24346
the lesion , a similar trend	24356
the lesion	24356
a similar trend	24368
week 1	24396
SCI	24409
this trend	24422
the later time-points	24449
The linear mixed model analysis	24472
significant interaction effects of Treatment × Position -LRB- p = 0.02 , F1 ,786 = 6.2 -RRB- and Treatment × Time postinjury × Position -LRB- p = 0.03 , F2 ,786 = 3.7 -RRB- and a close-to-significant effect of Treatment -LRB- p = 0.051 , F1 ,36 = 1.4 -RRB-	24511
significant interaction effects	24511
Treatment × Position -LRB- p = 0.02 , F1 ,786 = 6.2 -RRB- and Treatment × Time postinjury × Position -LRB- p = 0.03 , F2 ,786 = 3.7 -RRB- and a close-to-significant effect of Treatment -LRB- p = 0.051 , F1 ,36 = 1.4 -RRB-	24546
Treatment × Position -LRB- p = 0.02 , F1 ,786 = 6.2 -RRB- and Treatment × Time postinjury × Position -LRB- p = 0.03 , F2 ,786 = 3.7 -RRB-	24546
Treatment × Position -LRB- p = 0.02 , F1 ,786 = 6.2 -RRB-	24546
Treatment × Position	24546
p = 0.02 , F1 ,786 = 6.2	24566
p	24566
= 0.02 , F1 ,786 = 6.2	24567
= 0.02	24567
F1 ,786 = 6.2	24574
F1 ,786	24574
6.2	24581
Treatment × Time postinjury × Position -LRB- p = 0.03 , F2 ,786 = 3.7 -RRB-	24590
Treatment × Time	24590
postinjury × Position -LRB- p = 0.03 , F2 ,786 = 3.7 -RRB-	24605
postinjury × Position	24605
p = 0.03 , F2 ,786 = 3.7	24626
p	24626
= 0.03 , F2 ,786 = 3.7	24627
= 0.03	24627
F2 ,786 = 3.7	24634
F2 ,786	24634
3.7	24641
a close-to-significant effect of Treatment -LRB- p = 0.051 , F1 ,36 = 1.4 -RRB-	24650
a close-to-significant effect	24650
Treatment -LRB- p = 0.051 , F1 ,36 = 1.4 -RRB-	24683
Treatment	24683
p = 0.051 , F1 ,36 = 1.4	24694
p	24694
= 0.051 , F1 ,36 = 1.4	24695
= 0.051 , F1 ,36	24695
0.051	24696
1.4	24709
Post-hoc analysis	24715
a significant effect of Treatment	24739
a significant effect	24739
Treatment	24763
the rostral SPNs at week 9 post-injury -LRB- p = 0.007 , t58 = 2.7 , t-test -RRB-	24776
the rostral SPNs	24776
week 9 post-injury -LRB- p = 0.007 , t58 = 2.7 , t-test -RRB-	24796
week 9 post-injury	24796
week	24796
p	24816
= 0.007 , t58 = 2.7 , t-test	24817
= 0.007	24817
t58 = 2.7	24825
t58	24825
2.7	24829
t-test	24834
the control animals	24860
the dendritic length	24881
the pre-injury levels	24920
the previously described morphometric features	24950
the number of primary dendrites in theOEC-treated groups	24998
the number	24998
primary dendrites in theOEC-treated groups	25012
primary dendrites	25012
theOEC-treated groups	25033
showa consistent pattern of increase or decrease	25063
showa consistent pattern	25063
increase or decrease	25091
the control groups	25130
fact	25153
the linear mixed model analysis	25159
an interaction effect of Treatment × Time post-injury × Position	25197
an interaction effect	25197
Treatment × Time post-injury × Position	25222
Treatment × Time	25222
× Position	25249
primary dendrite numbers -LRB- p = 0.03 , F2 ,786 = 4.1 -RRB-	25262
primary dendrite numbers	25262
p = 0.03 , F2 ,786 = 4.1	25288
p	25288
= 0.03 , F2 ,786 = 4.1	25289
= 0.03	25289
F2 ,786 = 4.1	25296
F2 ,786	25296
Post-hoc analysis	25309
a significant effect of Treatment	25334
a significant effect	25334
Treatment	25358
the rostral SPNs at week 9 post-injury -LRB- p = 0.04 , t58 = 1.7 , t-test -RRB-	25371
the rostral SPNs	25371
week 9 post-injury -LRB- p = 0.04 , t58 = 1.7 , t-test -RRB-	25391
week 9 post-injury	25391
week	25391
p	25411
= 0.04 , t58 = 1.7 , t-test	25412
= 0.04	25412
t58 = 1.7	25419
t58	25419
1.7	25423
t-test	25428
summary	25440
soma size , dendritic length and number of primary dendrites	25449
soma size	25449
dendritic length and number of primary dendrites	25460
dendritic length and number	25460
primary dendrites	25491
SCI	25529
both rostral and caudal segments	25536
both rostral	25536
caudal segments	25553
This increase	25570
9 weeks for soma size	25598
9 weeks	25598
soma size	25610
the overall dendritic length and the number of primary dendrites	25647
the overall dendritic length	25647
the number of primary dendrites	25680
the number	25680
primary dendrites	25694
The significant effects of OECs	25713
The significant effects	25713
OECs	25740
9 weeks when they caused a reduction towards pre-injury values for caudal soma size and maintained the increase in the number and length of dendrites in the rostral cord	25766
9 weeks	25766
they	25779
a reduction	25791
pre-injury values for caudal soma size	25811
pre-injury values	25811
caudal soma size	25833
the increase	25865
the number and length of dendrites in the rostral cord	25881
the number and length	25881
dendrites in the rostral cord	25906
dendrites	25906
the rostral cord	25919
3.3	25937
Primary afferent fibre density in the dorsal horn The density of the CGRP-positive primary afferent fibres in laminae I , II , III+IV and V	25942
Primary afferent fibre density	25942
the dorsal horn The density of the CGRP-positive primary afferent fibres in laminae I , II , III+IV and V	25976
the dorsal horn The density	25976
the dorsal horn	25976
The density	25992
the CGRP-positive primary afferent fibres in laminae	26007
the CGRP-positive primary afferent fibres	26007
laminae	26052
I	26060
II	26063
III+IV	26067
the cross-sections	26096
the spinal cord at the T1 and T7 segments	26123
the spinal cord	26123
the T1 and T7 segments	26142
the intact animals and the animals	26168
the intact animals	26168
the animals	26191
1 and 4 weeks post-injury -LRB- the spinal cord tissue at week 9 was not available for this analysis -RRB-	26206
1 and 4 weeks	26206
the spinal cord tissue at week 9	26233
the spinal cord tissue	26233
week 9	26259
this analysis	26288
Fig. 6	26322
density of the CGRP-positive fibres in intact animals	26330
density	26330
the CGRP-positive fibres in intact animals	26341
the CGRP-positive fibres	26341
intact animals	26369
highest in laminae I and II	26388
highest	26388
laminae I and II	26399
laminae I	26399
II	26413
relatively low levels found in laminae III -- V. Following SCI	26422
relatively low levels found in laminae III	26422
relatively low levels	26422
laminae III	26453
V. Following SCI	26465
V.	26465
SCI	26478
CGRP density	26483
a trend to increase with time in laminae I -- IV , particularly caudal to the lesion	26503
time in laminae I -- IV , particularly caudal	26528
time	26528
laminae I -- IV , particularly caudal	26536
laminae I	26536
laminae	26536
I	26544
IV	26546
the lesion	26573
The increase in the lamina II	26585
The increase	26585
the lamina II	26601
the level of statistical significance -LRB- p = 0.04 , F2 ,29 = 4.3 , three-way ANOVA -RRB- , specifically	26623
the level	26623
statistical significance -LRB- p = 0.04 , F2 ,29 = 4.3 , three-way ANOVA -RRB- , specifically	26636
statistical significance -LRB- p = 0.04 , F2 ,29 = 4.3 , three-way ANOVA -RRB-	26636
statistical significance	26636
p = 0.04 , F2 ,29 = 4.3 , three-way ANOVA	26662
p = 0.04	26662
p	26662
0.04	26664
F2 ,29 = 4.3	26670
F2 ,29	26670
4.3	26676
three-way ANOVA	26681
three-way	26681
ANOVA	26691
the T7 segment	26715
week 4 post-injury -LRB- p = 0.05 , t5 = 2 , Tukey 's tests -RRB-	26733
week 4 post-injury	26733
week	26733
p = 0.05 , t5 = 2 , Tukey 's tests	26753
p = 0.05	26753
p	26753
0.05	26755
t5 = 2	26761
t5	26761
2	26764
Tukey 's tests	26767
Tukey 's	26767
tests	26775
No effect of the OEC transplantation on the afferent fibre density	26783
No effect	26783
the OEC transplantation on the afferent fibre density	26796
the OEC transplantation	26796
the afferent fibre density	26823
SPNs rostral or caudal to the lesion	26866
SPNs rostral or caudal	26866
the lesion	26892
The differences between the OEC-treated and the control groups	26904
The differences	26904
the OEC-treated and the control groups	26928
the OEC-treated	26928
the control groups	26948
any consistent trends	26995
This observation	27018
a three-way ANOVA -LRB- p ≥ 0.2 , F2 ,29 ≤ 1.8 -RRB-	27054
a three-way ANOVA	27054
p ≥ 0.2 , F2 ,29 ≤ 1.8	27073
p	27073
≥ 0.2 , F2 ,29 ≤ 1.8	27074
≥ 0.2	27074
F2 ,29 ≤ 1.8	27080
F2 ,29	27080
≤ 1.8	27085
Discussion	27096
the rat model of T4 transection	27113
the rat model	27113
T4 transection	27130
we	27146
complete SCI	27165
formation of gradually expanding cavities both rostral and caudal to the lesion	27187
formation	27187
cavities both rostral and caudal	27220
cavities	27220
rostral and caudal	27234
the lesion	27256
shrinkage of the spinal cord tissue , which occurs early after the insult and does not evolve further	27275
shrinkage	27275
the spinal cord tissue , which occurs early after the insult and does not evolve further	27288
the spinal cord tissue	27288
the insult	27337
the injury	27387
temporary as well as more prolonged changes in the morphology of SPNs adjacent to the lesion	27409
temporary as well as more prolonged changes	27409
the morphology of SPNs adjacent to the lesion	27456
the morphology	27456
SPNs adjacent to the lesion	27474
SPNs	27474
the lesion	27491
the CGRP-positive primary afferent fibres within the dorsal horn caudal	27529
the CGRP-positive primary afferent fibres	27529
the dorsal horn caudal	27578
the lesion	27604
we	27625
OEC transplants	27651
the changes in SPNs	27673
the changes	27673
SPNs	27688
the injury	27709
the injury-induced cavity formation	27731
the sprouting of CGRP-positive afferent fibres	27785
the sprouting	27785
CGRP-positive afferent fibres	27802
4.1	27833
Morphological changes within the spinal cord following T4 transection We have shown that transection of the spinal cord results in formation of cavities as well as in overall shrinkage of the nervous tissue , evidenced by narrowing of the cord near the injury site , both rostral and caudal to the lesion .	27838
Morphological changes	27838
the spinal cord following T4 transection We have shown that transection of the spinal cord results in formation of cavities	27867
the spinal cord	27867
T4 transection We have shown that transection of the spinal cord results in formation of cavities	27893
T4 transection	27893
We	27908
transection of the spinal cord	27927
transection	27927
the spinal cord	27942
formation of cavities	27969
formation	27969
cavities	27982
overall shrinkage of the nervous tissue , evidenced by narrowing of the cord near the injury site , both rostral and caudal to the lesion	28005
overall shrinkage of the nervous tissue , evidenced by narrowing of the cord near the injury site	28005
overall shrinkage	28005
the nervous tissue , evidenced by narrowing of the cord near the injury site	28026
the nervous tissue	28026
narrowing of the cord near the injury site	28059
narrowing	28059
the cord near the injury site	28072
the cord	28072
the injury site	28086
rostral and caudal to the lesion	28108
rostral and caudal	28108
the lesion	28130
These changes	28142
1 week of the traumatic event	28169
1 week	28169
the traumatic event	28179
the case of cavitation	28207
the case	28207
cavitation	28219
at least 9 weeks	28243
the extent of non-cavity tissue loss	28270
the extent	28270
non-cavity tissue loss	28284
1 week	28329
This	28349
the shrinkage of the injured cord	28369
the shrinkage	28369
the injured cord	28386
the expanding cavitation	28421
the direct result of retraction of the cut stumps at the time of transection	28457
the direct result	28457
retraction of the cut stumps at the time of transection	28478
retraction	28478
the cut stumps at the time of transection	28492
the cut stumps	28492
the time of transection	28510
the time	28510
transection	28522
formation of cavities	28547
formation	28547
cavities	28560
a sensitive marker of the spread of secondary injury	28580
a sensitive marker	28580
the spread of secondary injury	28602
the spread	28602
secondary injury	28616
one of the principal obstacles of the spinal cord regeneration	28640
one	28640
the principal obstacles of the spinal cord regeneration	28647
the principal obstacles	28647
the spinal cord regeneration	28674
we	28717
the cord transection	28735
an increase in soma size , overall dendritic length	28765
an increase	28765
soma size , overall dendritic length	28780
soma size	28780
overall dendritic length	28791
number of primary dendrites of the SPNs adjacent to the lesion	28823
number	28823
primary dendrites of the SPNs adjacent to the lesion	28833
primary dendrites	28833
the SPNs adjacent to the lesion	28854
the SPNs	28854
the lesion	28875
The dendritic changes	28887
9 weeks of SCI	28941
9 weeks	28941
SCI	28952
The increase in soma size of the SPNs	28957
The increase	28957
soma size of the SPNs	28973
soma size	28973
the SPNs	28986
a more permanent nature , as it is apparent at least until 9 weeks post-injury	29001
a more permanent nature	29001
it	29029
9 weeks	29059
The changes in soma size and in overall dendritic length	29080
The changes	29080
soma size	29095
overall dendritic length	29112
SPNs rostral	29160
those caudal to the lesion , while the changes in number of dendrites do not differ above and below the injury	29185
those	29185
the lesion , while the changes in number of dendrites do not differ above	29201
the lesion	29201
the changes in number of dendrites	29219
the changes	29219
number of dendrites	29234
number	29234
dendrites	29244
the injury	29284
The plasticity of a specific group of SPNs labelled from the adrenal medulla	29296
The plasticity	29296
a specific group of SPNs labelled from the adrenal medulla	29314
a specific group	29314
SPNs labelled from the adrenal medulla	29334
SPNs	29334
the adrenal medulla	29353
previous studies -LRB- Krassioukov and Weaver , 1995 , 1996 ; Krenz and Weaver , 1998a -RRB-	29394
previous studies	29394
Krassioukov and Weaver	29412
Krassioukov	29412
Weaver	29428
1995 , 1996 ; Krenz and Weaver , 1998a	29436
1995	29436
1996 ; Krenz and Weaver	29442
1996	29442
Krenz and Weaver	29448
1998a	29466
these earlier reports	29483
ours	29517
several critical aspects	29525
No changes in SPN morphology -LRB- soma size , dendritic length or number of primary dendrites -RRB-	29551
No changes in SPN morphology	29551
No changes	29551
SPN morphology	29565
soma size , dendritic length or number of primary dendrites	29581
soma size	29581
dendritic length	29592
number of primary dendrites	29612
number	29612
primary dendrites	29622
caudally all measures	29671
1 week	29708
injury	29721
Krassioukov and Weaver , 1995	29729
Krassioukov	29729
Weaver , 1995	29745
Weaver	29745
1995	29753
A later study	29760
these caudal changes	29788
2 weeks	29826
the appearance of these cells at longer time-points -LRB- day 30 -RRB-	29839
the appearance	29839
these cells at longer time-points -LRB- day 30 -RRB-	29857
these cells	29857
longer time-points -LRB- day 30 -RRB-	29872
longer time-points	29872
day 30	29892
this	29918
Krassioukov and Weaver	29947
1996	29971
Reasons for these discrepancies in SPN plasticity	29978
Reasons	29978
these discrepancies in SPN plasticity	29990
these discrepancies	29990
SPN plasticity	30013
all cases	30047
complete transections of the cord at similar levels -LRB- T4 here ; T5 in the cited works -RRB-	30057
complete transections	30057
the cord at similar levels -LRB- T4 here ; T5 in the cited works -RRB-	30082
the cord	30082
similar levels	30094
T4 here ; T5	30110
T4 here	30110
T5	30119
the cited works	30125
the compared studies	30157
the	30157
studies	30170
measurements of the same morphological features	30187
measurements	30187
the same morphological features	30203
It	30236
SPNs projecting to the adrenal gland	30256
SPNs	30256
the adrenal gland	30275
other SPNs	30317
Krassioukov and Weaver	30338
similar changes in morphology	30374
similar changes	30374
morphology	30393
all SPNs visualised by NADPH staining	30442
all SPNs	30442
NADPH staining	30465
Plasticity of SPNs	30495
Plasticity	30495
SPNs	30509
a likely mechanism contributing to the development of autonomic dysreflexia and clearly requires further investigation.We suggest that our observation of the transient increase in dendritic length and in number of primary dendrites as well as the more permanent increase in soma size in SPNs both rostral and caudal to the lesion could constitute a compensatory reaction of these neurons to the loss of a considerable proportion of their input -LRB- Llewellyn-Smith et al. , 2006 -RRB-	30517
a likely mechanism	30517
the development of autonomic dysreflexia	30552
the development	30552
autonomic dysreflexia	30571
further investigation.We suggest that our observation of the transient increase in dendritic length and in number of primary dendrites as well as the more permanent increase in soma size in SPNs both rostral and caudal to the lesion could constitute a compensatory reaction of these neurons to the loss of a considerable proportion of their input	30614
further investigation.We	30614
our observation of the transient increase in dendritic length and in number of primary dendrites as well as the more permanent increase in soma size in SPNs both rostral and caudal to the lesion	30652
our observation	30652
the transient increase in dendritic length and in number of primary dendrites as well as the more permanent increase in soma size in SPNs both rostral and caudal to the lesion	30671
the transient increase	30671
dendritic length	30697
number of primary dendrites as well as the more permanent increase in soma size in SPNs both rostral and caudal to the lesion	30721
number of primary dendrites	30721
number	30721
primary dendrites	30731
the more permanent increase in soma size in SPNs both rostral and caudal to the lesion	30760
the more permanent increase in soma size in SPNs	30760
the more permanent increase	30760
soma size in SPNs	30791
soma size	30791
SPNs	30804
rostral and caudal to the lesion	30814
rostral and caudal	30814
the lesion	30836
a compensatory reaction of these neurons	30864
a compensatory reaction	30864
these neurons	30891
the loss of a considerable proportion of their input	30908
the loss	30908
a considerable proportion of their input	30920
a considerable proportion	30920
their input	30949
Llewellyn-Smith	30962
et al. , 2006	30978
et al.	30978
2006	30986
Increase in the size of their somata and of their dendritic trees	30993
Increase	30993
the size of their somata	31005
the size	31005
their somata	31017
their dendritic trees	31037
an attempt to regain lost synapses	31078
lost synapses	31099
the decrease in the synaptic density reported on SPNs -LRB- Llewellyn-Smith and Weaver , 2001 -RRB-	31145
the decrease	31145
the synaptic density reported on SPNs -LRB- Llewellyn-Smith and Weaver , 2001 -RRB-	31161
the synaptic density	31161
SPNs -LRB- Llewellyn-Smith and Weaver , 2001 -RRB-	31194
SPNs	31194
Llewellyn-Smith and Weaver , 2001	31200
Llewellyn-Smith	31200
Weaver , 2001	31220
Weaver	31220
2001	31228
T4 transection	31244
a gradual increase in density of CGRP	31270
a gradual increase	31270
density of CGRP	31292
density	31292
CGRP	31303
positive primary afferent fibres in Rexed lamina II below the lesion -LRB- here tested within the segment T7 -RRB-	31308
positive primary afferent fibres	31308
Rexed lamina II below the lesion -LRB- here tested within the segment T7 -RRB-	31344
Rexed lamina II	31344
the lesion	31366
the segment T7	31397
This	31414
agreement	31425
earlier works , which reported a similar increase that could be attributed to the afferent fibre sprouting within the dorsal horn , particularly in the lower thoracic , lumbar and sacral segments -LRB- Christensen and Hulsebosch , 1997 ; Hou et al. , 2009 -RRB-	31440
earlier works	31440
a similar increase that could be attributed to the afferent fibre sprouting within the dorsal horn , particularly in the lower thoracic , lumbar and sacral segments -LRB- Christensen and Hulsebosch , 1997 ; Hou et al. , 2009 -RRB-	31470
a similar increase	31470
the afferent fibre sprouting within the dorsal horn , particularly in the lower thoracic , lumbar and sacral segments -LRB- Christensen and Hulsebosch , 1997 ; Hou et al. , 2009 -RRB-	31517
the afferent fibre	31517
the dorsal horn	31553
the lower thoracic , lumbar and sacral segments -LRB- Christensen and Hulsebosch , 1997 ; Hou et al. , 2009 -RRB-	31586
the lower thoracic , lumbar and sacral segments	31586
Christensen and Hulsebosch , 1997 ; Hou et al. , 2009	31634
Christensen and Hulsebosch	31634
1997 ; Hou et al.	31662
1997	31662
Hou et al.	31668
Hou	31668
et al.	31672
2009	31680
these works	31699
we	31712
the afferent fibre sprouting	31736
the afferent fibre	31736
the segments remote from the injury epicentre	31788
the segments remote	31788
the injury epicentre	31813
the segment T7 , i.e. three levels caudal to the lesion	31851
the segment T7	31851
i.e. three levels caudal to the lesion	31867
i.e.	31867
three levels	31872
the lesion	31895
This sprouting	31907
This	31907
nerve growth factor -LRB- NGF -RRB-	31950
nerve growth factor	31950
NGF	31971
the formation of abnormal connections	32007
the formation	32007
abnormal connections	32024
the caudal segments of the spinal cord that have been deprived of their descending regulatory inputs from supraspinal nuclei -LRB- Cameron et al. , 2006 ; Krenz and Weaver , 1998b -RRB-	32052
the caudal segments	32052
the spinal cord that have been deprived of their descending regulatory inputs from supraspinal nuclei -LRB- Cameron et al. , 2006 ; Krenz and Weaver , 1998b -RRB-	32075
the spinal cord	32075
their descending regulatory inputs	32118
supraspinal nuclei	32158
Cameron	32178
et al. , 2006 ; Krenz and Weaver , 1998b	32186
et al.	32186
2006 ; Krenz and Weaver	32194
2006	32194
Krenz and Weaver	32200
1998b	32218
It	32226
this abnormal intraspinal circuitry	32243
an important role in the development of pathological reflexes , such as autonomic dysreflexia	32285
an important role	32285
the development of pathological reflexes , such as autonomic dysreflexia	32306
the development	32306
pathological reflexes	32325
autonomic dysreflexia	32356
it	32388
the intraspinal plasticity triggered by the SCI	32413
the intraspinal plasticity	32413
the SCI	32453
augmentation of some physiological reflexes	32484
augmentation	32484
some physiological reflexes	32500
some of the autonomic functions , e.g. local response of vasculature	32560
some	32560
the autonomic functions , e.g. local response of vasculature	32568
the autonomic functions , e.g. local response	32568
functions , e.g.	32582
functions	32582
e.g.	32593
vasculature	32616
the change in the environmental temperature -LRB- Kalincik et al. , 2009 -RRB-	32631
the change	32631
the environmental temperature -LRB- Kalincik et al. , 2009 -RRB-	32645
the environmental temperature	32645
Kalincik	32676
et al. , 2009	32685
et al.	32685
2009	32693
4.2	32700
Effect of OECs on the morphological changes in the injured spinal cord We	32705
Effect	32705
OECs on the morphological changes in the injured spinal cord We	32715
OECs	32715
the morphological changes in the injured spinal cord We	32723
the morphological changes	32723
the injured spinal cord We	32752
a trend	32790
OEC transplantation	32802
cavity formation both rostral and caudal	32836
cavity formation	32836
rostral and caudal	32858
the spinal cord lesion , an effect that was previously described -LRB- Plant et al. , 2003 ; Ramer et al. , 2004 ; Verdu et al. , 2003 -RRB-	32880
the spinal cord lesion	32880
an effect that was previously described -LRB- Plant et al. , 2003 ; Ramer et al. , 2004 ; Verdu et al. , 2003 -RRB-	32904
an effect	32904
Plant et al. , 2003 ; Ramer et al. , 2004 ; Verdu et al. , 2003	32945
Plant	32945
et al. , 2003 ; Ramer et al. , 2004 ; Verdu et al. , 2003	32951
et al. , 2003	32951
et al.	32951
2003	32959
Ramer et al. , 2004	32965
Ramer	32965
et al. , 2004	32971
et al.	32971
2004	32979
Verdu et al. , 2003	32985
Verdu	32985
et al. , 2003	32991
et al.	32991
2003	32999
It	33006
our study	33050
the purpose of the cavity size analysis	33081
the purpose	33081
the cavity size analysis	33096
the level of statistical significance	33125
the level	33125
statistical significance	33138
week 9	33183
the other two time-points	33220
It	33247
OECs	33267
a protective effect on the nervous tissue adjacent to the lesion	33277
a protective effect	33277
the nervous tissue adjacent to the lesion	33300
the nervous tissue	33300
the lesion	33331
The OEC-mediated reduction in the spread of secondary injury	33343
The OEC-mediated reduction	33343
the spread of secondary injury	33373
the spread	33373
secondary injury	33387
a role	33415
the amelioration of autonomic dysreflexia	33425
the amelioration	33425
autonomic dysreflexia	33445
we	33471
elsewhere -LRB- Kalincik et al. , 2010 -RRB-	33484
elsewhere	33484
Kalincik	33495
et al. , 2010	33504
et al.	33504
2010	33512
the other hand	33522
overall shrinkage of the nervous tissue , here quantified as non-cavity tissue loss ,	33538
overall shrinkage	33538
the nervous tissue	33559
non-cavity tissue loss	33598
the OEC transplantation	33643
our hypothesis that non-cavity tissue loss develops immediately after the traumatic event and thereafter remains static	33681
our hypothesis	33681
non-cavity tissue loss	33701
the traumatic event	33751
static	33794
it	33802
the therapeutic regimens , whose morphological and structural effects become obvious only days or weeks after SCI	33837
the therapeutic regimens	33837
morphological and structural effects	33869
obvious only days or weeks	33913
SCI	33946
The changes in the morphometric features initiated by the spinal cord transection	33951
The changes	33951
the morphometric features initiated by the spinal cord transection	33966
the morphometric features	33966
the spinal cord transection	34005
9 weeks	34046
the OEC transplantation	34060
it	34088
the data from our previous work -LRB- Kalincik et al. , 2010 -RRB-	34104
the data	34104
our previous work -LRB- Kalincik et al. , 2010 -RRB-	34118
our previous work	34118
Kalincik	34137
et al. , 2010	34146
et al.	34146
2010	34154
it	34166
the treatment with OECs	34186
the treatment	34186
OECs	34205
soma size of the SPNs	34229
soma size	34229
the SPNs	34242
the injury	34261
the prolonged trend of the SPNs	34281
the prolonged trend	34281
the SPNs	34304
their soma size	34325
the trauma	34347
This phenomenon	34371
a decreased reactivity of the propriospinal circuits	34399
a decreased reactivity	34399
the propriospinal circuits	34425
the injury	34458
the stimuli	34472
the abnormal autonomic responses	34495
their overall impact	34552
The fact that similar normalisation in SPN soma size is not seen above the lesion	34574
The fact	34574
similar normalisation in SPN soma size	34588
similar normalisation	34588
SPN soma size	34613
the lesion	34645
the intact descending regulation of the rostral SPNs from the supraspinal centres	34677
the intact descending regulation	34677
the rostral SPNs from the supraspinal centres	34713
the rostral SPNs	34713
the supraspinal centres	34735
the OEC-treated animals	34770
a more permanent increase	34799
the overall dendritic length of the rostral SPNs	34828
the overall dendritic length	34828
the rostral SPNs	34860
the control animals	34894
This trend	34915
first apparent at week 4 -LRB- p = 0.09 , t5 = 1.5 , post-hoc t-test -RRB-	34934
first	34934
week 4	34952
p	34960
= 0.09 , t5 = 1.5 , post-hoc t-test	34961
= 0.09	34961
t5 = 1.5	34968
t5	34968
1.5	34971
post-hoc t-test	34976
the statistical significance	35009
week 9	35041
It	35049
the increase in dendritic trees of the rostral SPNs , which are involved in the baroreflex ,	35069
the increase	35069
dendritic trees of the rostral SPNs	35085
dendritic trees	35085
the rostral SPNs	35104
the baroreflex	35144
the episodic arterial hypertension associated with the autonomic dysreflexia -LRB- Mathias and Frankel , 1986 -RRB-	35180
the episodic arterial hypertension	35180
the autonomic dysreflexia -LRB- Mathias and Frankel , 1986 -RRB-	35231
the autonomic dysreflexia	35231
Mathias and Frankel , 1986	35258
Mathias and Frankel	35258
1986	35279
Larger dendritic arbours	35286
the regulatory function of SPNs	35328
the regulatory function	35328
SPNs	35355
augmented interconnections	35368
other neurons of the baroreflex circuits	35400
other neurons	35400
the baroreflex circuits	35417
This hypothesis	35442
further supported by the observation that no similar changes in the dendritic arbours are seen caudally	35461
further	35461
the observation	35482
no similar changes in the dendritic arbours	35503
no similar changes	35503
the dendritic arbours	35525
The increase in the number of primary dendrites	35566
The increase	35566
the number of primary dendrites	35582
the number	35582
primary dendrites	35596
overall dendritic length	35642
Transplantation of OECs	35668
Transplantation	35668
OECs	35687
any effect on CGRP afferent fibre density within the dorsal horn of the injured spinal cord neither rostral nor caudal to the lesion	35706
any effect	35706
CGRP afferent fibre density within the dorsal horn of the injured spinal cord neither rostral nor caudal to the lesion	35720
CGRP	35720
afferent fibre density within the dorsal horn of the injured spinal cord neither rostral	35725
afferent fibre density	35725
the dorsal horn of the injured spinal cord neither rostral	35755
the dorsal horn	35755
the injured spinal cord neither rostral	35774
the injured spinal cord	35774
rostral	35806
the lesion	35828
Similar to the control animals , the injury-induced increase in the CGRP fibre density within lamina II of the T7 segment	35840
Similar	35840
the control animals , the injury-induced increase in the CGRP fibre density within lamina II of the T7 segment	35851
the control animals	35851
the injury-induced increase in the CGRP fibre density within lamina II of the T7 segment	35872
the injury-induced increase	35872
the CGRP fibre density within lamina II of the T7 segment	35903
the CGRP fibre density	35903
lamina II of the T7 segment	35933
lamina II	35933
the T7 segment	35946
week 9 post-injury	35976
week	35976
the transplantation of the OECs	36027
the transplantation	36027
the OECs	36050
it	36070
the functional effects of OEC transplantation on autonomic dysreflexia	36090
the functional effects	36090
OEC transplantation on autonomic dysreflexia	36116
OEC transplantation	36116
autonomic dysreflexia	36139
CGRP positive primary afferents rostral or caudal to the spinal cord lesion	36195
CGRP positive primary afferents rostral or caudal	36195
the spinal cord lesion	36248
4.3	36272
Interactions between the OECs and the host	36277
Interactions	36277
the OECs and the host	36298
the OECs	36298
the host	36311
nervous tissue In the present study we used a previously described technique of placing an OEC-seeded Gelfoam block at the transection site immediately after the traumatic event , which yields a limited -LRB- i.e. 3 weeks -RRB- survival of OECs at the lesion	36320
nervous tissue	36320
the present study	36338
we	36356
a previously described technique of placing an OEC-seeded Gelfoam block at the transection site immediately after the traumatic event , which yields a limited -LRB- i.e. 3 weeks -RRB- survival of OECs at the lesion	36364
a previously described technique	36364
an OEC-seeded Gelfoam block	36408
the transection site	36439
the traumatic event , which yields a limited -LRB- i.e. 3 weeks -RRB- survival of OECs at the lesion	36478
the traumatic event	36478
a limited -LRB- i.e. 3 weeks -RRB- survival of OECs at the lesion	36512
a limited -LRB- i.e. 3 weeks -RRB- survival	36512
i.e. 3 weeks	36523
i.e.	36523
3 weeks	36528
OECs at the lesion	36549
OECs	36549
the lesion	36557
Kalincik et al. , 2010	36569
Kalincik	36569
et al.	36578
2010	36586
We	36593
even this transitory presence of OECs at the injury site	36614
even this transitory presence	36614
OECs at the injury site	36647
OECs	36647
the injury site	36655
long-term functional as well as morphological changes , which outlast their survival	36681
long-term functional as well as morphological changes	36681
their survival	36750
a phenomenon	36765
Guest et al. , 2008 ; Lopez-Vales et al. , 2006 ; Ramer et al. , 2004	36803
Guest	36803
et al. , 2008 ; Lopez-Vales et al. , 2006 ; Ramer et al. , 2004	36809
et al. , 2008	36809
et al.	36809
2008	36817
Lopez-Vales et al. , 2006	36823
Lopez-Vales	36823
et al. , 2006	36835
et al.	36835
2006	36843
Ramer et al. , 2004	36849
Ramer	36849
et al. , 2004	36855
et al.	36855
2004	36863
there	36885
a marked gap between the period of OEC survival and the observation of the statistically significant changes in cavity size and in SPN morphology	36894
a marked gap	36894
the period of OEC survival and the observation of the statistically significant changes in cavity size and in SPN morphology	36915
the period of OEC survival	36915
the period	36915
OEC survival	36929
the observation of the statistically significant changes in cavity size and in SPN morphology	36946
the observation	36946
the statistically significant changes in cavity size and in SPN morphology	36965
the statistically significant changes	36965
cavity size	37006
SPN morphology	37025
the changes in dendritic length and cavity formation	37054
the changes	37054
dendritic length and cavity formation	37069
the observed trends	37108
4 weeks of transection , i.e. shortly	37156
4 weeks of transection , i.e.	37156
4 weeks	37156
transection	37167
the OECs	37199
the host spinal cord	37229
we	37261
the observed changes	37279
they	37328
week 9	37369
It	37377
the model of OEC transplantation that we used in the present study	37411
the model	37411
OEC transplantation that we used in the present study	37424
OEC transplantation	37424
we	37449
the present study	37460
the lesion	37510
axons	37526
β-tubulin III	37572
the previously reported functional improvement -LRB- Kalincik et al. , 2010 -RRB-	37591
the previously reported functional improvement	37591
Kalincik	37639
et al. , 2010	37648
et al.	37648
2010	37656
reconnection of the transected spinal cord	37686
reconnection	37686
the transected spinal cord	37702
OECs	37730
neuronal morphology	37759
both direct contact and secretion of soluble factors -LRB- Chung et al. , 2004 -RRB-	37787
both direct contact and secretion	37787
soluble factors -LRB- Chung et al. , 2004 -RRB-	37824
soluble factors	37824
Chung	37841
et al. , 2004	37847
et al.	37847
2004	37855
our previous study	37865
we	37884
migration of the OECs	37899
migration	37899
the OECs	37912
we	37925
their effects	37943
the soluble factors	37987
OECs	38008
a range of growth factors such as NGF , brain-derived neurotrophic factor -LRB- BDNF -RRB- and glia cell line-derived growth factor -LRB- GDNF -RRB- -LRB- Woodhall et al. , 2001 -RRB-	38034
a range	38034
growth factors such as NGF , brain-derived neurotrophic factor -LRB- BDNF -RRB- and glia cell line-derived growth factor -LRB- GDNF -RRB- -LRB- Woodhall et al. , 2001 -RRB-	38045
growth factors such as NGF , brain-derived neurotrophic factor -LRB- BDNF -RRB-	38045
growth factors	38045
NGF , brain-derived neurotrophic factor -LRB- BDNF -RRB-	38068
NGF	38068
brain-derived neurotrophic factor -LRB- BDNF -RRB-	38073
brain-derived neurotrophic factor	38073
BDNF	38108
glia cell line-derived growth factor -LRB- GDNF -RRB- -LRB- Woodhall et al. , 2001 -RRB-	38118
glia cell	38118
line-derived growth factor -LRB- GDNF -RRB- -LRB- Woodhall et al. , 2001 -RRB-	38128
line-derived growth factor -LRB- GDNF -RRB-	38128
line-derived growth factor	38128
GDNF	38156
Woodhall	38163
et al. , 2001	38172
et al.	38172
2001	38180
involvement of NGF in the OEC effect	38196
involvement	38196
NGF in the OEC effect	38211
NGF	38211
the OEC effect	38218
NGF	38259
augmented sprouting of CGRP positive afferent fibres -LRB- Christensen and Hulsebosch , 1997 -RRB- , not seen in our OEC-treated animals	38282
augmented sprouting	38282
CGRP positive afferent fibres	38305
Christensen and Hulsebosch	38336
1997	38364
our OEC-treated animals	38383
OECs	38421
the duration of autonomic dysreflexia -LRB- Kalincik et al. , 2010 -RRB-	38433
the duration	38433
autonomic dysreflexia -LRB- Kalincik et al. , 2010 -RRB-	38449
autonomic dysreflexia	38449
Kalincik	38472
et al. , 2010	38481
et al.	38481
2010	38489
primary afferent fibre sprouting	38502
primary afferent fibre	38502
its exacerbation -LRB- Krenz et al. , 1999 -RRB-	38551
its exacerbation	38551
Krenz	38569
et al. , 1999	38575
et al.	38575
1999	38583
the other hand	38593
BDNF and GDNF	38609
the morphometric properties of SPNs	38646
the morphometric properties	38646
SPNs	38677
BDNF	38683
an increase	38699
size of the SPN somata and axons	38714
size	38714
the SPN somata and axons	38722
the SPN somata	38722
axons	38741
synaptic input to postganglionic neurons -LRB- Causing et al. , 1997 -RRB-	38761
synaptic input	38761
postganglionic neurons	38779
et al. , 1997	38811
et al.	38811
1997	38819
GDNF	38832
the capacity to protect SPNs from target-deprived cell death -LRB- Schober et al. , 1999 -RRB-	38841
SPNs	38865
target-deprived cell death -LRB- Schober et al. , 1999 -RRB-	38875
target-deprived cell death	38875
Schober	38903
et al. , 1999	38911
et al.	38911
1999	38919
release of BDNF and GDNF by transplanted OECs	38936
release	38936
BDNF and GDNF by transplanted OECs	38947
BDNF and GDNF	38947
transplanted OECs	38964
a potential mechanism for their effect	38996
a potential mechanism	38996
their effect	39022
SPNs	39038
the spinal cord tissue preservation described here	39059
the spinal cord tissue preservation	39059
We	39111
the differential effect of OEC treatment on the SPNs rostral and caudal to the SCI	39145
the differential effect	39145
OEC treatment on the SPNs rostral and caudal to the SCI	39172
OEC treatment	39172
the SPNs rostral and caudal to the SCI	39189
the SPNs rostral and caudal	39189
the SCI	39220
a difference in the activity-dependent demand for trophic factors	39242
a difference	39242
the activity-dependent demand for trophic factors	39258
the activity-dependent demand	39258
trophic factors	39292
the injury	39324
The SPNs rostral to the injury	39336
The SPNs rostral	39336
the injury	39356
innervation	39394
an organised manner under the control of supraspinal centres	39427
an	39427
manner	39440
the control of supraspinal centres	39453
the control	39453
supraspinal centres	39468
contrast	39492
SPNs	39502
the transection loose	39517
the transection	39517
their descending inputs , which further emphasises the role of the rostral SPNs in the compensation for low baseline blood pressure and dysreflexic hypertension	39539
their descending inputs	39539
the role of the rostral SPNs in the compensation for low baseline blood pressure and dysreflexic hypertension	39589
the role	39589
the rostral SPNs in the compensation for low baseline blood pressure and dysreflexic hypertension	39601
the rostral SPNs	39601
the compensation for low baseline blood pressure and dysreflexic hypertension	39621
the compensation	39621
low baseline blood pressure and dysreflexic hypertension	39642
low baseline blood pressure	39642
dysreflexic hypertension	39674
it	39710
the demand of the rostral SPNs for neurotrophic factors as well as the overall effect of these factors on their morphology and function	39730
the demand	39730
the rostral SPNs for neurotrophic factors as well as the overall effect of these factors on their morphology and function	39744
the rostral SPNs for neurotrophic factors	39744
the rostral SPNs	39744
neurotrophic factors	39765
the overall effect of these factors on their morphology and function	39797
the overall effect	39797
these factors on their morphology and function	39819
these factors	39819
their morphology and function	39836
that of the SPNs caudal to the injury	39879
that	39879
the SPNs caudal to the injury	39887
the SPNs	39887
the injury	39906
Such activity dependence	39918
development , when neurotrophins act as modulators of activity-dependent plasticity -LRB- reviewed in Bibel and Barde , 2000 -RRB- ; for instance , the effect of BDNF on dendritic length and branching in retinal ganglion cells depends on their activity -LRB- Cohen-Cory , 1999 -RRB-	39964
development	39964
neurotrophins	39982
modulators of activity-dependent plasticity -LRB- reviewed in Bibel and Barde , 2000 -RRB- ; for instance , the effect of BDNF on dendritic length and branching in retinal ganglion cells	40003
modulators	40003
activity-dependent plasticity -LRB- reviewed in Bibel and Barde , 2000 -RRB- ; for instance , the effect of BDNF on dendritic length and branching in retinal ganglion cells	40017
activity-dependent plasticity -LRB- reviewed in Bibel and Barde , 2000 -RRB-	40017
activity-dependent plasticity	40017
Bibel and Barde , 2000	40060
Bibel and Barde	40060
2000	40077
instance	40088
the effect of BDNF on dendritic length and branching in retinal ganglion cells	40098
the effect	40098
BDNF	40112
dendritic length	40120
retinal ganglion cells	40154
their activity -LRB- Cohen-Cory , 1999 -RRB-	40188
their activity	40188
Cohen-Cory	40204
1999	40216
contrast to the specific effects of OECs on SPN morphology	40226
contrast	40226
the specific effects of OECs on SPN morphology	40238
the specific effects	40238
OECs on SPN morphology	40262
OECs	40262
SPN morphology	40270
the effect of OEC transplantation on cavity formation	40286
the effect	40286
OEC transplantation on cavity formation	40300
OEC transplantation	40300
cavity formation	40323
the lesion	40367
This	40379
OECs	40398
cavitation via a more general neuroprotective mechanism , such as modulation of inflammation -LRB- Lopez-Vales et al. , 2006 -RRB-	40420
cavitation	40420
a more general neuroprotective mechanism	40435
modulation of inflammation -LRB- Lopez-Vales et al. , 2006 -RRB-	40485
modulation	40485
inflammation -LRB- Lopez-Vales et al. , 2006 -RRB-	40499
inflammation	40499
Lopez-Vales	40513
et al. , 2006	40525
et al.	40525
2006	40533
The present work	40540
some of the potential mechanisms through which transplantation of OECs contributes to the amelioration of autonomic dysreflexia in spinal cord-injured animals	40566
some	40566
the potential mechanisms through which transplantation of OECs contributes to the amelioration of autonomic dysreflexia in spinal cord-injured animals	40574
the potential mechanisms	40574
transplantation of OECs	40613
transplantation	40613
OECs	40632
the amelioration of autonomic dysreflexia in spinal cord-injured animals	40652
the amelioration	40652
autonomic dysreflexia in spinal cord-injured animals	40672
autonomic dysreflexia	40672
spinal cord-injured animals	40697
cellular therapies for SCI	40732
cellular therapies	40732
SCI	40755
significant scientific attention with clinical trials undertaken -LRB- Mackay-Sim et al. , 2008 -RRB-	40773
significant scientific attention	40773
clinical trials undertaken	40811
clinical trials	40811
Mackay-Sim	40839
et al. , 2008	40850
et al.	40850
2008	40858
research on effects other than merely locomotion	40865
research	40865
effects other than merely locomotion	40877
effects	40877
merely locomotion	40896
safety	40941
human subjects	40951
more scientific work is needed before the mechanisms of OEC actions on these functions	40976
more scientific work	40976
the mechanisms of OEC actions	41014
the mechanisms	41014
OEC actions	41032
these functions	41047
